{ "version": "2.2", "instance": { "pkbo-20231231.htm": { "nsprefix": "pkbo", "nsuri": "http://peak-bio.com/20231231", "dts": { "inline": { "local": [ "pkbo-20231231.htm" ] }, "schema": { "local": [ "pkbo-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" ] } }, "keyStandard": 316, "keyCustom": 149, "axisStandard": 32, "axisCustom": 1, "memberStandard": 30, "memberCustom": 72, "hidden": { "total": 10, "http://fasb.org/us-gaap/2023": 6, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 382, "entityCount": 1, "segmentCount": 114, "elementCount": 912, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 836, "http://xbrl.sec.gov/dei/2023": 36, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://peak-bio.com/20231231/taxonomy/role/CoverPage", "longName": "100000 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets", "longName": "100010 - Statement - BALANCE SHEETS", "shortName": "BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:AssetsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R3": { "role": "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheetsParentheticals", "longName": "100030 - Statement - BALANCE SHEETS (Parentheticals)", "shortName": "BALANCE SHEETS (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R5": { "role": "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit", "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF EQUITY (DEFICIT)", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY (DEFICIT)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_115d7926-1c41-46d4-9995-fbdbe618e2fb", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_115d7926-1c41-46d4-9995-fbdbe618e2fb", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R6": { "role": "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows", "longName": "100070 - Statement - STATEMENTS OF CASH FLOWS", "shortName": "STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ShareBasedCompensation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_38cbe59f-866f-443f-8e45-82554e30da01", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_38cbe59f-866f-443f-8e45-82554e30da01", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R9": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusiness", "longName": "995455 - Disclosure - Description of the Business", "shortName": "Description of the Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R10": { "role": "http://peak-bio.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R11": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssets", "longName": "995475 - Disclosure - Assets", "shortName": "Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpenses", "longName": "995485 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensation", "longName": "995495 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCosts1", "longName": "995505 - Disclosure - Related Party Transactions and Shared Service Costs", "shortName": "Related Party Transactions and Shared Service Costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeases3", "longName": "995515 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://peak-bio.com/20231231/taxonomy/role/CommitmentsAndContingencies", "longName": "995525 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreements", "longName": "995535 - Disclosure - Collaborative and Licensing Agreements", "shortName": "Collaborative and Licensing Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquity", "longName": "995545 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1", "longName": "995555 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenue", "longName": "995565 - Disclosure - Grant Revenue", "shortName": "Grant Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebt", "longName": "995575 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxes", "longName": "995585 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://peak-bio.com/20231231/taxonomy/role/SubsequentEvents", "longName": "995595 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_b0e05842-974a-43f5-a0cb-9ce4a27b2571", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b0e05842-974a-43f5-a0cb-9ce4a27b2571", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995625 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://peak-bio.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "995635 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "pkbo:ScheduleOfNumberOfSharesOfCommonStockIssuedImmediatelyFollowingTheConsummationOfTheBusinessCombinationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R26": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsTables", "longName": "995645 - Disclosure - Assets (Tables)", "shortName": "Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "pkbo:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextblock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "pkbo:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextblock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables", "longName": "995655 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureShareBasedCompensationTables", "longName": "995665 - Disclosure - Share -Based Compensation (Tables)", "shortName": "Share -Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtTables", "longName": "995675 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_60b1c19f-b873-4dcf-b5b4-e26171600310", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_60b1c19f-b873-4dcf-b5b4-e26171600310", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R30": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsTables", "longName": "995685 - Disclosure - Related Party Transactions and Shared Service Costs (Tables)", "shortName": "Related Party Transactions and Shared Service Costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesTables", "longName": "995695 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "pkbo:QuantitativeInformationRegardingCompanysLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "pkbo:QuantitativeInformationRegardingCompanysLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables", "longName": "995705 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables", "longName": "995715 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables", "longName": "995725 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "longName": "995735 - Disclosure - Description of the Business (Details)", "shortName": "Description of the Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_03e59cac-4814-4462-9e73-46130447c130", "name": "us-gaap:SharePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_59c090e8-cee9-4058-a68c-12da20f23a3a", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R36": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995745 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "pkbo:RestrictedBankAccountCollateralForCreditCard", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R37": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails", "longName": "995755 - Disclosure - Summary of Significant Accounting Policies - Schedule of Components of net Transfers from pH Pharma (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Components of net Transfers from pH Pharma (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_bab06f02-16ba-418f-b2c6-2de6463c9b1e", "name": "pkbo:RelatedPartyTransactionResearchAndDevelopment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bab06f02-16ba-418f-b2c6-2de6463c9b1e", "name": "pkbo:RelatedPartyTransactionResearchAndDevelopment", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNumberOfSharesOfCommonStockIssuedImmediatelyFollowingTheConsummationOfTheBusine", "longName": "995765 - Disclosure - Summary of Significant Accounting Policies - Schedule of Number Of Shares of Common Stock Issued Immediately Following the Consummation of the Business Combination (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Number Of Shares of Common Stock Issued Immediately Following the Consummation of the Business Combination (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_d2758ea6-2771-4abb-8ae4-7fa982d892f5", "name": "pkbo:BusinessCombinationCommonStockSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d2758ea6-2771-4abb-8ae4-7fa982d892f5", "name": "pkbo:BusinessCombinationCommonStockSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashFlowsRelatedBusinessCombinationDetails", "longName": "995775 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash Flows Related Business Combination (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash Flows Related Business Combination (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "pkbo:RestrictedCashForwardSharePurchaseAgreement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e535dbb2-8687-473d-a71d-c98a12717bdb", "name": "pkbo:CashTransactionCostsAllocatedToTheCompanysEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "pkbo:ScheduleOfReconciliationOfCashFlowsRelatingBusinessCombinationTableTextBlock", "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R40": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail", "longName": "995785 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Changes In Stockholders' Equity (Deficit) Related Business Combination (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Changes In Stockholders' Equity (Deficit) Related Business Combination (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "pkbo:RestrictedCashForwardSharePurchaseAgreement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e535dbb2-8687-473d-a71d-c98a12717bdb", "name": "pkbo:FairValueOfPrivateWarrants", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "pkbo:ScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatingBusinessCombinationTableTextBlock", "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R41": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "longName": "995795 - Disclosure - Summary of Significant Accounting Policies - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "pkbo:CashIgnyteTrustAndCashNetOfRedemptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "pkbo:CashIgnyteTrustAndCashNetOfRedemptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "ix:continuation", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueOfSharebasedAwardsMeasuredWithWeightedaverageAssumptionsDetails", "longName": "995805 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value of Share-based Awards Measured with Weighted-Average Assumptions (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Fair Value of Share-based Awards Measured with Weighted-Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_47470154-e1e4-4223-ac6a-32e7bf0dc772", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails", "longName": "995815 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities Excluded from Calculation of Net Loss Per Share (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Dilutive Securities Excluded from Calculation of Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_12cd4bd4-8ba8-4ead-ac53-9d49eb203649", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_12cd4bd4-8ba8-4ead-ac53-9d49eb203649", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsScheduleOfPrepaidAndOtherCurrentAssetsDetails", "longName": "995825 - Disclosure - Assets - Schedule of Prepaid and Other Current Assets (Details)", "shortName": "Assets - Schedule of Prepaid and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "pkbo:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextblock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "pkbo:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextblock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails", "longName": "995835 - Disclosure - Assets - Summary of Property and Equipment (Details)", "shortName": "Assets - Summary of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R46": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsAdditionalInformationDetails", "longName": "995845 - Disclosure - Assets - Additional Information (Details)", "shortName": "Assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8b87ec6e-2ff4-4574-95e4-727671444706", "name": "us-gaap:Depreciation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R47": { "role": "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails", "longName": "995855 - Disclosure - Initial Public Offering (Details)", "shortName": "Initial Public Offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_03e59cac-4814-4462-9e73-46130447c130", "name": "us-gaap:SharePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": null }, "R48": { "role": "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails", "longName": "995865 - Disclosure - Private Placement (Details)", "shortName": "Private Placement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_03e59cac-4814-4462-9e73-46130447c130", "name": "us-gaap:SharePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails", "longName": "995875 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_4ab3575e-2844-47a9-96e4-93e7c4934248", "name": "pkbo:AnnualEscalations", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4ab3575e-2844-47a9-96e4-93e7c4934248", "name": "pkbo:AnnualEscalations", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfQuantitativeInformationRegardingCompanysLeasesDetails", "longName": "995885 - Disclosure - Leases - Summary of Quantitative Information Regarding Company's Leases (Details)", "shortName": "Leases - Summary of Quantitative Information Regarding Company's Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "pkbo:QuantitativeInformationRegardingCompanysLeasesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "pkbo:QuantitativeInformationRegardingCompanysLeasesTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R51": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails", "longName": "995905 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)", "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:AccruedProfessionalFeesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R52": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails", "longName": "995915 - Disclosure - Accrued Expenses - Additional Information (Details)", "shortName": "Accrued Expenses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:OtherLiabilitiesNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:OtherAccruedLiabilitiesNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R53": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "longName": "995925 - Disclosure - Share-Based Compensation - Additional Information (Details)", "shortName": "Share-Based Compensation - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R54": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails", "longName": "995935 - Disclosure - Share-Based Compensation - Summary of option activity (Details)", "shortName": "Share-Based Compensation - Summary of option activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_c9011084-cc40-42ed-859f-ebb7547c9614", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R55": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseDetails", "longName": "995945 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)", "shortName": "Share-Based Compensation - Schedule of Share-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_77aba924-9afc-4d22-b855-a2bb0dbc7b02", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R56": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails", "longName": "995955 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0a2aa5ae-7395-4f4f-8f4b-db952571e650", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R57": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "longName": "995965 - Disclosure - Fair Value of Financial Instruments - Summary of Changes In Level 3 Liabilities (Assets) Measured At Fair Value On Recurring Basis (Details)", "shortName": "Fair Value of Financial Instruments - Summary of Changes In Level 3 Liabilities (Assets) Measured At Fair Value On Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_c9011084-cc40-42ed-859f-ebb7547c9614", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_944a29e1-b226-457c-b34e-29710fb50ed3", "name": "pkbo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInceptionDate", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R58": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "longName": "995975 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)", "shortName": "Fair Value of Financial Instruments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_47470154-e1e4-4223-ac6a-32e7bf0dc772", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9ebf765f-3f3c-42b5-ba0a-d4e8dc8cdb5f", "name": "pkbo:PercentageOfDiscountRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R59": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "longName": "995985 - Disclosure - Fair Value of Financial Instruments - Schedule of Weighted Average Assumptions Used in Determining the Fair Value (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Weighted Average Assumptions Used in Determining the Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_8af3b63d-4976-4b29-9708-7f4974056589", "name": "us-gaap:SharePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_1c2f7906-5ff4-44f1-829d-d899754b8d15", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R60": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "longName": "995995 - Disclosure - Related Party Transactions and Shared Service Costs - Additional Information (Details)", "shortName": "Related Party Transactions and Shared Service Costs - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_b0e05842-974a-43f5-a0cb-9ce4a27b2571", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e07c00f4-0020-46a9-9523-9e19869184c7", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R61": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "996005 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_80eb7af4-1529-4890-a7a2-8932507d22c1", "name": "pkbo:MilestonesPaymentAggregateAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_80eb7af4-1529-4890-a7a2-8932507d22c1", "name": "pkbo:MilestonesPaymentAggregateAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R62": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreementsAdditionalInformationDetails", "longName": "996015 - Disclosure - Collaborative and Licensing Agreements - Additional Information (Details)", "shortName": "Collaborative and Licensing Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_618b9ad5-4398-4378-80ae-0d26f061598e", "name": "pkbo:Upfrontpaymentreceived", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R63": { "role": "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "longName": "996025 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_c9011084-cc40-42ed-859f-ebb7547c9614", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b0e05842-974a-43f5-a0cb-9ce4a27b2571", "name": "pkbo:ChangeinFairvalueOfDerivativeLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R64": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfStockOptionsDetails", "longName": "996035 - Disclosure - Stockholders' Equity - Schedule of Weighted Average Assumptions Used in Determining Fair Value of Stock Options (Details)", "shortName": "Stockholders' Equity - Schedule of Weighted Average Assumptions Used in Determining Fair Value of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_47470154-e1e4-4223-ac6a-32e7bf0dc772", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2fba2b01-4f46-4ec9-96e5-fdf7e8c70d46", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R65": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails", "longName": "996045 - Disclosure - Stockholders' Equity - Summary of Company's Outstanding Warrants (Details)", "shortName": "Stockholders' Equity - Summary of Company's Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_f7f6caa1-9925-409a-81e8-338f72759cac", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3043d39d-5407-4c65-8080-45775872236c", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R66": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "longName": "996055 - Disclosure - Grant Revenue - Additional Information (Details)", "shortName": "Grant Revenue - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_e465b4fb-64eb-4aa6-8f98-273565933951", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:RevenueRecognitionPolicyTextBlock", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_bd0acfc0-6ed8-456d-ae76-6e5a2cc400aa", "name": "pkbo:RevenueFromGrantsRemainingFundingCapacity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R67": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "longName": "996065 - Disclosure - Debt - Additional Information (Details)", "shortName": "Debt - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_ba83eb65-e59c-4191-97ca-91f35ad7acbd", "name": "us-gaap:ProceedsFromRelatedPartyDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_7cd996ef-f7c3-4792-83f0-2dfe408cd2c2", "name": "pkbo:PromissoryNoteAssumed", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R68": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "longName": "996075 - Disclosure - Debt - Additional Information 1 (Details)", "shortName": "Debt - Additional Information 1 (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_ba83eb65-e59c-4191-97ca-91f35ad7acbd", "name": "us-gaap:ProceedsFromRelatedPartyDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_bdee12a6-2b34-4f37-9a58-6b62d6f9eaf7", "name": "us-gaap:FinancialGuaranteeInsuranceContractsPremiumReceivable", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R69": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueStockOptionsDetails", "longName": "996085 - Disclosure - Debt - Schedule of Weighted Average Assumptions Used in Determining the Fair Value Stock Options (Details)", "shortName": "Debt - Schedule of Weighted Average Assumptions Used in Determining the Fair Value Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_47470154-e1e4-4223-ac6a-32e7bf0dc772", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_60b1c19f-b873-4dcf-b5b4-e26171600310", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R70": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails", "longName": "996095 - Disclosure - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)", "shortName": "Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R71": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails", "longName": "996105 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)", "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_b0e05842-974a-43f5-a0cb-9ce4a27b2571", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b0e05842-974a-43f5-a0cb-9ce4a27b2571", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R72": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails", "longName": "996115 - Disclosure - Income Taxes - Schedule of Reconciliation of the Federal Income Tax Effective Rate (Details)", "shortName": "Income Taxes - Schedule of Reconciliation of the Federal Income Tax Effective Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R73": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "996125 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_16191222-3a2e-45a5-a6f5-3049ee464dcb", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } }, "R74": { "role": "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails", "longName": "996135 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets (Liabilities) (Details)", "shortName": "Income Taxes - Schedule of Components of Deferred Tax Assets (Liabilities) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_880f02a5-430f-4cde-8ee2-1e01897755bd", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true, "unique": true } }, "R75": { "role": "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails", "longName": "996145 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "C_b67cafb0-a8fa-472f-85ea-3b70beeb7351", "name": "us-gaap:DebtInstrumentIssuedPrincipal", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2d5fe2fd-6c77-438a-a569-78057528b34c", "name": "us-gaap:ProceedsFromRepaymentsOfSecuredDebt", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "pkbo-20231231.htm", "unique": true } } }, "tag": { "pkbo_AcceleratedPurchaseNoticeLimitPercentage": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AcceleratedPurchaseNoticeLimitPercentage", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated Purchase Notice Limit", "label": "Accelerated Purchase Notice Limit, Percentage", "documentation": "Percentage limit of accelerated purchase notice ." } } }, "auth_ref": [] }, "pkbo_AcceleratedPurchasePriceDiscountingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AcceleratedPurchasePriceDiscountingPercentage", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated purchase price discount", "label": "Accelerated Purchase Price Discounting Percentage", "documentation": "Percentage by which the accelerated purchase price is discounted." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r30" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29", "r823" ] }, "pkbo_AccountsPayableRelatedPartiesCurrent1": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AccountsPayableRelatedPartiesCurrent1", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable Related Parties Current", "label": "Accounts Payable Related Parties Current 1", "documentation": "Accounts payable related parties current 1." } } }, "auth_ref": [] }, "pkbo_AccretionOfDiscountOnConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AccretionOfDiscountOnConvertibleNotesPayable", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of discount on convertible notes payable", "label": "Accretion Of Discount On Convertible Notes Payable", "documentation": "Accretion of discount on convertible notes payable." } } }, "auth_ref": [] }, "pkbo_AccretionOfOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AccretionOfOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of the operating lease liability", "label": "Accretion of Operating Lease Liability", "documentation": "Accretion of operating lease liability." } } }, "auth_ref": [] }, "pkbo_AccrualAdministrativeServiceFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AccrualAdministrativeServiceFeesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrual Administrative Service Fees Member", "terseLabel": "Accrual of Administrative Service Fees [Member]", "label": "AccrualAdministrativeServiceFeesMember" } } }, "auth_ref": [] }, "pkbo_AccruedContractResearchAndDevelopmentCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AccruedContractResearchAndDevelopmentCostsCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued contract research and development costs current.", "label": "Accrued Contract Research And Development Costs Current", "terseLabel": "Contract research and development costs" } } }, "auth_ref": [] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Accrued Employee Benefits, Current", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r33" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total accrued expenses", "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r33" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "label": "Accrued Liabilities", "totalLabel": "Accrued Liabilities, Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities." } } }, "auth_ref": [ "r97" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Professional Fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r33" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation", "negatedLabel": "Less: accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r63", "r187", "r618" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r42", "r43", "r116", "r194", "r614", "r642", "r646" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r15", "r43", "r510", "r513", "r548", "r637", "r638", "r944", "r945", "r946", "r958", "r959", "r960" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r877" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "totalLabel": "Additional Paid in Capital, Total", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r109", "r823", "r1056" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r462", "r463", "r464", "r660", "r958", "r959", "r960", "r1025", "r1058" ] }, "pkbo_AdditionalPipeSubscriptionAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AdditionalPipeSubscriptionAgreementsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional PIPE subscription agreements", "label": "Additional PIPE Subscription Agreements [Member]", "terseLabel": "Additional PIPE Subscription Agreement [Member]" } } }, "auth_ref": [] }, "pkbo_AdditionalPipeWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AdditionalPipeWarrants", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional pipe warrants", "label": "Additional PIPE Warrants", "documentation": "Additional pipe warrants." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r883" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r883" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r883" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r883" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r74", "r75", "r425" ] }, "pkbo_AggregateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AggregateAmount", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate amount (in Dollars)", "label": "Aggregate Amount", "documentation": "Aggregate amount." } } }, "auth_ref": [] }, "pkbo_AggregateGrossPurchasePriceOfNewlyIssuedShares": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AggregateGrossPurchasePriceOfNewlyIssuedShares", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate gross purchase price of newly issued shares.", "label": "Aggregate Gross Purchase Price Of Newly Issued Shares", "terseLabel": "Aggregate gross purchase price" } } }, "auth_ref": [] }, "pkbo_AggregatePriceOfPurchaseNoticeShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AggregatePriceOfPurchaseNoticeShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate price of purchase notice shares.", "label": "Aggregate Price Of Purchase Notice Shares", "terseLabel": "Aggregate price of purchase notice shares" } } }, "auth_ref": [] }, "pkbo_AggregatePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AggregatePrincipalAmount", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate Principal Amount", "label": "Aggregate Principal Amount", "terseLabel": "Aggregate Principal amount" } } }, "auth_ref": [] }, "pkbo_AggregatePurchaseAmountOfShare": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AggregatePurchaseAmountOfShare", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate purchase amount of share.", "label": "Aggregate Purchase Amount Of Share", "terseLabel": "Aggregate purchase amount of shares" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r847", "r859", "r869", "r895" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r850", "r862", "r872", "r898" ] }, "pkbo_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AgreementAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement Axis", "label": "Agreement [Axis]" } } }, "auth_ref": [] }, "pkbo_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AgreementDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement Domain", "label": "Agreement [Domain]" } } }, "auth_ref": [] }, "pkbo_AkariAmericanDepositarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AkariAmericanDepositarySharesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Akari American depositary shares", "label": "Akari American Depositary Shares [Member]", "documentation": "Akari American depositary shares." } } }, "auth_ref": [] }, "pkbo_AkariOrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AkariOrdinarySharesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Akari ordinary shares", "label": "Akari Ordinary Shares [Member]", "documentation": "Akari ordinary shares." } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r883" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r890" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r854", "r863", "r873", "r890", "r899", "r903", "r911" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r909" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total equity-based compensation", "verboseLabel": "Share based combensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r457", "r469" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount premium", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r10", "r91", "r122", "r374" ] }, "pkbo_AnnualEscalations": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AnnualEscalations", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Annual escalations.", "label": "Annual Escalations", "verboseLabel": "Annual escalations" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential common shares for outstanding warrants (in Shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Anti-dilutive securities excluded from earnings per share calculation", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r255" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r56" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r56" ] }, "pkbo_April2023ConversionFeatureLiability1Member": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "April2023ConversionFeatureLiability1Member", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Conversion Feature Liability [Member]", "label": "April 2023 Conversion Feature Liability1 [Member]", "documentation": "April 2023 Conversion feature liability." } } }, "auth_ref": [] }, "pkbo_April2023ConversionFeatureLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "April2023ConversionFeatureLiabilityMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtTables", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Conversion Feature Liability", "label": "April 2023 Conversion Feature Liability [Member]", "documentation": "April 2023 Conversion Feature Liability." } } }, "auth_ref": [] }, "pkbo_April2023ConversionFeatureLiabilityRelatedToConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "April2023ConversionFeatureLiabilityRelatedToConvertibleNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Conversion Feature Liability Related To Convertible Notes", "label": "April 2023 Conversion Feature Liability Related To Convertible Notes [Member]", "documentation": "April 2023 Conversion Feature Liability Related To Convertible Notes [Member]" } } }, "auth_ref": [] }, "pkbo_April2023ConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "April2023ConvertibleNoteMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Convertible Note [Member]", "label": "April 2023 Convertible Note [Member]", "documentation": "April 2023 convertible note." } } }, "auth_ref": [] }, "pkbo_April2023ConvertibleNoteWarrantsAndPrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "April2023ConvertibleNoteWarrantsAndPrivatePlacementWarrantsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Convertible Note Warrants and Placement Agent Warrants [Member]", "label": "April 2023 Convertible Note Warrants and Private Placement Warrants [Member]", "documentation": "April 2023 convertible note warrants and private placement warrants." } } }, "auth_ref": [] }, "pkbo_April2023ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "April2023ConvertibleNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Convertible Notes [Member]", "label": "April 2023 Convertible Notes [Member]", "documentation": "April 2023 convertible notes." } } }, "auth_ref": [] }, "pkbo_April2023ConvertibleNotesUnderRelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "April2023ConvertibleNotesUnderRelatedPartyMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Convertible Notes Under Related Party [Member]", "label": "April 2023 Convertible Notes Under Related Party [Member]", "documentation": "April 2023 Convertible Notes under related party." } } }, "auth_ref": [] }, "pkbo_April2023ConvertibleNotesWarrantsLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "April2023ConvertibleNotesWarrantsLiabilityMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Convertible Notes Warrants Liability [Member]", "label": "April 2023 Convertible Notes Warrants Liability [Member]", "documentation": "April 2023 Convertible Notes Warrants Liability." } } }, "auth_ref": [] }, "pkbo_AprilTwoThousandTwentyThreeConvertibleNoteWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AprilTwoThousandTwentyThreeConvertibleNoteWarrantsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April 2023 Convertible Note Warrants [Member]", "label": "April Two Thousand Twenty Three Convertible Note Warrants [Member]", "documentation": "April two thousand twenty three convertible note warrants." } } }, "auth_ref": [] }, "pkbo_AprilTwoThousandTwentyThreeConvertibleNoteWarrantsRelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AprilTwoThousandTwentyThreeConvertibleNoteWarrantsRelatedPartyMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "April Two Thousand Twenty Three Convertible Note Warrants Related Party [Member]", "label": "April Two Thousand Twenty Three Convertible Note Warrants Related Party [Member]", "documentation": "April two thousand twenty three convertible note warrants related party." } } }, "auth_ref": [] }, "pkbo_AprilTwoThousandTwentyThreeConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AprilTwoThousandTwentyThreeConvertibleNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "April Two Thousand Twenty Three Convertible Notes [Member]", "label": "April Two Thousand Twenty Three Convertible Notes [Member]", "documentation": "April two thousand twenty three convertible notes [Member]" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreementsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r501" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r151", "r190", "r222", "r260", "r273", "r277", "r317", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r503", "r507", "r525", "r610", "r703", "r823", "r836", "r984", "r985", "r1038" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets Acquired" } } }, "auth_ref": [] }, "pkbo_AssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AssetsAcquired", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Assets acquired", "label": "Assets Acquired", "documentation": "Assets acquired" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "terseLabel": "Total current assets", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r183", "r196", "r222", "r317", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r503", "r507", "r525", "r823", "r984", "r985", "r1038" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r841", "r842", "r855" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r841", "r842", "r855" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r841", "r842", "r855" ] }, "pkbo_AutomaticConversionFeatureMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "AutomaticConversionFeatureMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Automatic Conversion Feature [Member]", "label": "Automatic Conversion Feature [Member]", "documentation": "Automatic conversion feature." } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r906" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r907" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r902" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r902" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r902" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r902" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r902" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r902" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r452", "r453", "r454", "r455", "r456" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r905" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r904" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r903" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r903" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "pkbo_BayerAcquisitionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "BayerAcquisitionAgreementMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bayer Acquisition Agreement [Member]", "label": "Bayer Acquisition Agreement [Member]", "documentation": "Bayer acquisition agreement." } } }, "auth_ref": [] }, "pkbo_BridgeLoanPipeSubscriberMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "BridgeLoanPipeSubscriberMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Bridge loan PIPE subscriber.", "label": "Bridge Loan PIPE Subscriber [Member]" } } }, "auth_ref": [] }, "pkbo_BridgeLoanPipeSubscriptionAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "BridgeLoanPipeSubscriptionAgreementsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Bridge Loan Pipe Subscription Agreements Member", "label": "Bridge Loan PIPE Subscription Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r500", "r815", "r816" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r80", "r81", "r500", "r815", "r816" ] }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses incurred", "label": "Business Acquisition, Transaction Costs", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": [] }, "pkbo_BusinessCombinationCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "BusinessCombinationCommonStockSharesOutstanding", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNumberOfSharesOfCommonStockIssuedImmediatelyFollowingTheConsummationOfTheBusine" ], "lang": { "en-us": { "role": { "periodEndLabel": "Total shares of common stock immediately after business combination on November 1, 2022", "periodStartLabel": "Common stock redeemable and outstanding prior to business combination on September 30, 2022", "label": "Business Combination Common Stock Shares Outstanding", "documentation": "Business combination common stock shares outstanding." } } }, "auth_ref": [] }, "pkbo_BusinessCombinationExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "BusinessCombinationExercisePrice", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "documentation": "Business combination exercise price.", "label": "Business Combination Exercise Price", "terseLabel": "Business combination exercise price" } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusiness" ], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "verboseLabel": "Description of the Business", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r101", "r128", "r129" ] }, "pkbo_CapitalContributionFromExtinguishmentOfIgnyteSponsorPromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CapitalContributionFromExtinguishmentOfIgnyteSponsorPromissoryNote", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Contribution from Extinguishment of Ignyte Sponsor Promissory Note", "label": "Capital Contribution from Extinguishment of Ignyte Sponsor Promissory Note", "documentation": "Capital Contribution from extinguishment of ignyte sponsor promissory note." } } }, "auth_ref": [] }, "pkbo_CapitalContributionFromParent": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CapitalContributionFromParent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Capital contribution from pH Pharma Ltd .", "documentation": "Capital contribution from parent.", "label": "Capital Contribution From Parent" } } }, "auth_ref": [] }, "pkbo_CapitalContributionUsingBlackScholesOptionPricingModel": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CapitalContributionUsingBlackScholesOptionPricingModel", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital contribution using black scholes option pricing model", "label": "Capital Contribution Using Black Scholes Option Pricing Model", "documentation": "Capital Contribution Using Black Scholes Option Pricing Model" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchase of property and equipment included in accounts payable", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r52", "r53", "r54" ] }, "pkbo_CapitalizedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CapitalizedResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Capitalized research and development.", "label": "Capitalized Research and Development", "terseLabel": "Capitalized Section 174 R&D" } } }, "auth_ref": [] }, "pkbo_CapitalizedStartUpCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CapitalizedStartUpCosts", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Capitalized Start up Costs", "documentation": "Amount of set up cost capitalized." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash and Cash Equivalents, at Carrying Value", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r49", "r185", "r786" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r50", "r150" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and restricted cash, beginning of year", "periodEndLabel": "Cash and restricted cash, end of year", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "totalLabel": "Total cash, cash equivalents and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r49", "r125", "r218" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Components of cash, cash equivalents and restricted cash" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "terseLabel": "Net (decrease) increase in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r125" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal depository insurance coverage", "label": "Cash, FDIC Insured Amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "pkbo_CashIgnyteTrustAndCashNetOfRedemptions": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CashIgnyteTrustAndCashNetOfRedemptions", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash - Ignyte Trust and Cash, Net of Redemptions", "label": "Cash - Ignyte Trust and Cash, Net of Redemptions", "documentation": "Cash - Ignyte Trust and Cash, Net of Redemptions" } } }, "auth_ref": [] }, "pkbo_CashIgnyteTrustAndCashNetOfRedemptionsAndPipeProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CashIgnyteTrustAndCashNetOfRedemptionsAndPipeProceeds", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashFlowsRelatedBusinessCombinationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash - Ignyte trust and cash, net of redemptions and PIPE proceeds", "label": "Cash - Ignyte Trust and Cash, Net of Redemptions and PIPE Proceeds", "documentation": "Cash - Ignyte trust and cash, net of redemptions and PIPE proceeds" } } }, "auth_ref": [] }, "pkbo_CashTransactionCostsAllocatedToTheCompanysEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CashTransactionCostsAllocatedToTheCompanysEquity", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashFlowsRelatedBusinessCombinationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: cash transaction costs allocated to the Company's equity", "label": "Cash Transaction Costs Allocated to the Company's Equity", "documentation": "Cash transaction costs allocated to the company's equity" } } }, "auth_ref": [] }, "pkbo_ChangeInFairValueOfConvertibleNotePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ChangeInFairValueOfConvertibleNotePayable", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Change in fair value of convertible note payable.", "label": "Change in Fair Value of Convertible Note Payable", "terseLabel": "Change in fair value of convertible note payable" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r881" ] }, "pkbo_ChangeinFairvalueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ChangeinFairvalueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of derivative liability", "label": "Changein FairValue Of Derivative Liability", "documentation": "Changein fairValue of derivative liability." } } }, "auth_ref": [] }, "pkbo_ChangeinFairvalueOfDerivativeLiabilityForwardPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ChangeinFairvalueOfDerivativeLiabilityForwardPurchaseAgreement", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of derivative liability forward purchase agreement", "label": "ChangeIn FairValue Of Derivative Liability Forward Purchase Agreement", "documentation": "ChangeIn fairValue of derivative liability forward purchase agreement." } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Officers [Member]", "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r967" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r178", "r191", "r192", "r193", "r222", "r249", "r250", "r252", "r254", "r258", "r259", "r317", "r343", "r345", "r346", "r347", "r350", "r351", "r382", "r383", "r386", "r389", "r396", "r525", "r650", "r651", "r652", "r653", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r691", "r712", "r735", "r762", "r763", "r764", "r765", "r766", "r919", "r952", "r964" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price per share", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r397" ] }, "pkbo_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ClassOfWarrantOrRightIssued", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right issued", "label": "Class Of Warrant Or Right Issued", "documentation": "Class of warrant or right issued." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants issued (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r397" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Number of Warrants", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r70" ] }, "pkbo_ClassOfWarrantOrRightTermFromWhichWarrantsOrRightsExercisable": { "xbrltype": "durationItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ClassOfWarrantOrRightTermFromWhichWarrantsOrRightsExercisable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, term from which warrants or rights exercisable.", "label": "Class of Warrant or Right, Term from which Warrants or Rights Exercisable", "verboseLabel": "Class of warrant or right, term from which warrants or rights exercisable" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r882" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r882" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreements" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative and Licensing Agreements", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r163", "r165", "r177" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r501" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "totalLabel": "Commitments and Contingencies, Total", "terseLabel": "Commitments and Contingencies (Note 8)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r39", "r98", "r611", "r690" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r134", "r335", "r336", "r769", "r978" ] }, "pkbo_CommitmentsandContingenciesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CommitmentsandContingenciesDetailsLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitmentsand Contingencies Details Line Items", "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "auth_ref": [] }, "pkbo_CommitmentsandContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CommitmentsandContingenciesDetailsTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitmentsand Contingencies Details Table", "label": "Commitments and Contingencies (Details) [Table]" } } }, "auth_ref": [] }, "pkbo_CommonStockConvertibleExchangeRatio": { "xbrltype": "pureItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CommonStockConvertibleExchangeRatio", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Common stock convertible exchange ratio.", "label": "Common Stock Convertible Exchange Ratio", "terseLabel": "Common stock convertible exchange ratio" } } }, "auth_ref": [] }, "pkbo_CommonStockIssuedToPeakBioShareholders1": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CommonStockIssuedToPeakBioShareholders1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNumberOfSharesOfCommonStockIssuedImmediatelyFollowingTheConsummationOfTheBusine" ], "lang": { "en-us": { "role": { "terseLabel": "Peak Bio shareholders", "label": "Common Stock Issued To Peak Bio Shareholders 1", "documentation": "Common stock issued to Peak Bio shareholders." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock [Member]", "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r826", "r827", "r828", "r830", "r831", "r832", "r833", "r958", "r959", "r1025", "r1053", "r1058" ] }, "pkbo_CommonStockOfIgnyte1": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CommonStockOfIgnyte1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNumberOfSharesOfCommonStockIssuedImmediatelyFollowingTheConsummationOfTheBusine" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock of Ignyte", "label": "Common Stock Of Ignyte 1", "documentation": "Common stock of Ignyte." } } }, "auth_ref": [] }, "us-gaap_CommonStockOtherSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockOtherSharesOutstanding", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total proceeds per share", "label": "Common Stock, Other Shares, Outstanding", "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheetsParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Par value of common shares issued (in Dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r108" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheetsParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares authorized", "terseLabel": "Common Stock, Shares Authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r108", "r691" ] }, "pkbo_CommonStockSharesForfeiture": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CommonStockSharesForfeiture", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock Shares Forfeiture", "label": "CommonStockSharesForfeiture", "documentation": "Number of shares of common stock forfeiture." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheetsParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares issued", "terseLabel": "Common Stock, Shares, Issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r108" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheetsParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares outstanding", "terseLabel": "Common Stock, Shares, Outstanding", "label": "Common Stock, Shares, Outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r16", "r108", "r691", "r709", "r1058", "r1059" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, par value of $0.0001 per share; 60,000,000 shares authorized; 23,124,888 shares issued and outstanding as of December 31, 2023 and 21,713,248 shares issued and 19,782,747 issued and outstanding as of December 31, 2022", "label": "Common Stock, Value, Issued", "terseLabel": "Common Stock Value, Purchase price", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r108", "r613", "r823" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r887" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r886" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r888" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r885" ] }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r44", "r202", "r204", "r211", "r606", "r624" ] }, "pkbo_ComputerAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ComputerAndOfficeEquipmentMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Computer and office equipment.", "label": "Computer and Office Equipment [Member" } } }, "auth_ref": [] }, "pkbo_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ComputerSoftwareMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Computer software.", "label": "Computer Software [Member]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of credit risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r99", "r167" ] }, "pkbo_ConsiderationPaymentOptionInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ConsiderationPaymentOptionInCash", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Consideration payment option in cash", "label": "Consideration Payment Option in Cash" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r230", "r503", "r504", "r507", "r508", "r557", "r780", "r983", "r986", "r987" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r230", "r503", "r504", "r507", "r508", "r557", "r780", "r983", "r986", "r987" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r399", "r400", "r411" ] }, "pkbo_ConversionRate": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ConversionRate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion Rate", "label": "Conversion Rate", "documentation": "Conversion rate." } } }, "auth_ref": [] }, "pkbo_ConvertibleNoteWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ConvertibleNoteWarrants", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible note warrants", "label": "Convertible Note Warrants", "documentation": "Convertible note warrants." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Outstanding balance of convertible notes", "totalLabel": "Convertible Notes Payable, Total", "label": "Convertible Notes Payable", "terseLabel": "Unsecured convertible promissory note", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r28", "r154", "r1049" ] }, "pkbo_ConvertibleNotesPayableAndDerivativeLiabilityAssumedInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ConvertibleNotesPayableAndDerivativeLiabilityAssumedInBusinessCombination", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Convertible notes payable and derivative liability assumed in Business Combination.", "label": "Convertible Notes Payable and Derivative Liability Assumed in Business Combination", "terseLabel": "Convertible notes payable and derivative liability assumed in Business Combination" } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes", "label": "Convertible Notes Payable, Current", "verboseLabel": "Issuance of convertible note", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible Notes", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r103", "r152" ] }, "pkbo_ConvertiblePromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ConvertiblePromissoryNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Convertible promissory notes.", "label": "Convertible Promissory Notes [Member]", "terseLabel": "Convertible Promissory Notes" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r227", "r228", "r356", "r384", "r555", "r788", "r790" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "pkbo_Covid19TherapeuticMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "Covid19TherapeuticMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "COVID 19 therapeutic.", "label": "COVID 19 Therapeutic [Member]" } } }, "auth_ref": [] }, "pkbo_CurrencyAndCurrencyTranslationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "CurrencyAndCurrencyTranslationPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Currency and currency translation.", "label": "Currency and Currency Translation [Policy Text Block]", "terseLabel": "Currency and currency translation" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "lang": { "en-us": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Current - Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r933", "r955", "r1022" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r146", "r488", "r494", "r955" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "Current - State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r933", "r955", "r1022" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Conversion of loan, shares", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r52", "r54" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r135", "r220", "r352", "r358", "r359", "r360", "r361", "r362", "r363", "r368", "r375", "r376", "r378" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r28", "r103", "r104", "r152", "r154", "r230", "r353", "r354", "r355", "r356", "r357", "r359", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r535", "r799", "r800", "r801", "r802", "r803", "r953" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, exchange amount", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion." } } }, "auth_ref": [ "r65" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price per share", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r136", "r355" ] }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible number of equity instruments", "label": "Debt Instrument, Convertible, Number of Equity Instruments", "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity." } } }, "auth_ref": [ "r36", "r68", "r138", "r139", "r355" ] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Weighted average price of common stock", "verboseLabel": "Convertible notes conversion price, threshold percentage", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Trading days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion of Accrued interest", "label": "Debt Instrument, Increase, Accrued Interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": [ "r953" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Default Interest Rate", "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r35", "r92", "r371" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r35", "r92", "r380", "r535" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r35", "r354" ] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Principal Amount", "terseLabel": "Related party loan, Principal amount", "label": "Debt Instrument, Issued, Principal", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": [ "r650" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Maturity date", "label": "Debt Instrument, Maturity Date", "terseLabel": "Loan, maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r175", "r799", "r1027" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r37", "r230", "r353", "r354", "r355", "r356", "r357", "r359", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r535", "r799", "r800", "r801", "r802", "r803", "r953" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "pkbo_December2022PipeMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "December2022PipeMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2022 PIPE [Member]", "label": "December 2022 PIPE [Member]", "documentation": "December 2022 PIPE." } } }, "auth_ref": [] }, "pkbo_December2023ConversionFeatureLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "December2023ConversionFeatureLiabilityMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2023 Conversion Feature Liability [Member]", "label": "December 2023 Conversion Feature Liability [Member]", "documentation": "December 2023 Conversion Feature Liability." } } }, "auth_ref": [] }, "pkbo_December2023ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "December2023ConvertibleNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2023 Convertible Notes [Member]", "label": "December 2023 Convertible Notes [Member]", "documentation": "December 2023 convertible notes." } } }, "auth_ref": [] }, "pkbo_December2023ConvertibleNotesUnderRelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "December2023ConvertibleNotesUnderRelatedPartyMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "December 2023 Convertible Notes Under Related Party [Member]", "label": "December 2023 Convertible Notes Under Related Party [Member]", "documentation": "December 2023 Convertible Notes under related party." } } }, "auth_ref": [] }, "pkbo_December2023PlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "December2023PlacementAgentMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "December 2023 Placement Agent [Member]", "label": "December 2023 Placement Agent [Member]", "documentation": "December 2023 Placement Agent." } } }, "auth_ref": [] }, "pkbo_DecemberTwoThousandTwentyThreeConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DecemberTwoThousandTwentyThreeConvertibleNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "December Two Thousand Twenty Three Convertible Notes [Member]", "label": "December Two Thousand Twenty Three Convertible Notes [Member]", "documentation": "December two thousand twenty three convertible notes." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Deferred - Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r955", "r1021", "r1022" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Deferred - Foreign", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r146", "r955", "r1021" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r10", "r146", "r173", "r493", "r494", "r955" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred Tax Liabilities, Gross, Total", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r105", "r106", "r153", "r482" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "Deferred - State", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r955", "r1021", "r1022" ] }, "pkbo_DeferredTaxAssetsForeignAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DeferredTaxAssetsForeignAccruals", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred tax assets foreign accruals.", "label": "Deferred Tax Assets Foreign Accruals", "terseLabel": "Foreign Accruals" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r483" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1019" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net decrease of valuation allowance", "totalLabel": "Deferred Tax Assets, Net of Valuation Allowance, Total", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Total net deferred tax assets", "negatedTotalLabel": "Total net deferred tax assets", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1019" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic", "terseLabel": "Net operating loss carryforwards", "verboseLabel": "Federal Net Operating Loss", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards." } } }, "auth_ref": [ "r79", "r1020" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "terseLabel": "Foreign Net Operating Loss", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards." } } }, "auth_ref": [ "r79", "r1020" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local", "terseLabel": "State Net Operating Loss", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards." } } }, "auth_ref": [ "r79", "r1020" ] }, "pkbo_DeferredTaxAssetsRightOfUseOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DeferredTaxAssetsRightOfUseOperatingLease", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred tax assets right of use operating lease.", "label": "Deferred Tax Assets Right of Use Operating Lease", "terseLabel": "Right of Use Operating Lease ASC 842" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards, Foreign", "terseLabel": "Foreign Tax Credits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards." } } }, "auth_ref": [ "r78", "r79", "r1020" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "terseLabel": "Accruals", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities." } } }, "auth_ref": [ "r79", "r1020" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax asset and valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Less: valuation allowance", "negatedTerseLabel": "Less: valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r484" ] }, "pkbo_DeferredTaxLiabilitiesDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DeferredTaxLiabilitiesDepreciation", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities depreciation.", "label": "Deferred Tax Liabilities Depreciation", "negatedTerseLabel": "Depreciation" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net [Abstract]" } } }, "auth_ref": [] }, "pkbo_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities operating lease right-of-use assets.", "label": "Deferred Tax Liabilities Operating Lease Right Of Use Assets", "negatedTerseLabel": "Right of Use Operating Lease ASC 842" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Total", "label": "Depreciation", "terseLabel": "Allocation of depreciation expense", "verboseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r10", "r62" ] }, "pkbo_DerivativeAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DerivativeAssetMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Derivative asset member.", "label": "Derivative Asset [Member]", "terseLabel": "Derivative Asset [Member]" } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsCurrent", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Derivative Asset, Current", "terseLabel": "Derivative asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r198" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "terseLabel": "Fair value of derivative liability", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r26", "r86", "r115", "r197", "r790" ] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Derivative, Fair Value, Net", "totalLabel": "Derivative, Fair Value, Net, Total", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": [ "r524" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in fair value", "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Change in fair value of derivative liability", "terseLabel": "Change in fair value of derivative liability", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r1024" ] }, "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative." } } }, "auth_ref": [ "r1024" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of Derivative Liability", "label": "Derivative Liability", "totalLabel": "Derivative Liability, Total", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r198", "r199", "r524", "r672", "r673", "r674", "r675", "r677", "r678", "r679", "r681", "r682", "r704", "r706", "r707", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r790", "r1054" ] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value as of beginning", "periodEndLabel": "Fair value as of ending", "label": "Derivative Liability, Current", "terseLabel": "Derivative liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r198" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Noncurrent", "terseLabel": "Warrant liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r198" ] }, "us-gaap_DerivativeLiabilityFairValueOfCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityFairValueOfCollateral", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Fair Value of Collateral", "terseLabel": "Embedded derivative liability fair value", "verboseLabel": "Derivative liability fair value of collateral", "documentation": "Fair value of securities pledged as collateral against derivative liabilities." } } }, "auth_ref": [ "r200" ] }, "us-gaap_DerivativeLiabilityMeasurementDifferenceDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityMeasurementDifferenceDescription", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of derivative liability, Description", "label": "Derivative Liability, Measurement Difference Description", "documentation": "Description of measurement difference between recognized amounts and resulting measurement differences for derivative liabilities." } } }, "auth_ref": [ "r114" ] }, "pkbo_DerivativeLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DerivativeLiabilityMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Derivative Liability [Member]", "label": "Derivative Liability [Member]", "terseLabel": "Derivative Liability [Member]" } } }, "auth_ref": [] }, "pkbo_DerivativeLiabilityNet": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DerivativeLiabilityNet", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability, net", "label": "Derivative Liability, Net", "documentation": "Derivative liability, net" } } }, "auth_ref": [] }, "pkbo_DerivativeLiabilityOnForwardSharePurchaseAgreement1": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DerivativeLiabilityOnForwardSharePurchaseAgreement1", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: derivative liability on Forward Share Purchase Agreement", "verboseLabel": "Derivative liability on Forward Share Purchase Agreement", "terseLabel": "Less: derivative liability on Forward Share Purchase Agreement", "label": "Derivative Liability On Forward Share Purchase Agreement 1", "documentation": "Derivative liability on forward share purchase agreement 1." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Instruments", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r17", "r82", "r83", "r84", "r88", "r229" ] }, "pkbo_DirectorLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DirectorLoansMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Director Loans [Member]", "label": "Director Loans [Member]", "documentation": "Director loans." } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director [Member]", "label": "Director [Member]" } } }, "auth_ref": [ "r967", "r1055" ] }, "pkbo_DirectorNomineeMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DirectorNomineeMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director Nominee [Member]", "documentation": "Director nominee.", "label": "Director Nominee [Member]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r410", "r805", "r806", "r807", "r808", "r809", "r810", "r811" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r410", "r805", "r806", "r807", "r808", "r809", "r810", "r811" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r423", "r427", "r458", "r459", "r461", "r818" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r841", "r842", "r855" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r841", "r842", "r855", "r891" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information Line Items", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r876" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated ByReference", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r838" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "terseLabel": "U.S", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "pkbo_DueToRelatedPartiesCurrent1": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "DueToRelatedPartiesCurrent1", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Related party loans", "label": "Due To Related Parties Current 1", "documentation": "Due to related parties current." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Basic net loss per share (in Dollars per share)", "verboseLabel": "Basic and diluted net (loss) income per share", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r212", "r236", "r237", "r239", "r240", "r242", "r247", "r249", "r252", "r253", "r254", "r256", "r519", "r520", "r607", "r625", "r792" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net loss per share (in Dollars per share)", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r212", "r236", "r237", "r239", "r240", "r242", "r249", "r252", "r253", "r254", "r256", "r519", "r520", "r607", "r625", "r792" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r56", "r57" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r526" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income Tax Provision/(Benefit)", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate", "verboseLabel": "Income Tax Provision/(Benefit)", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r476" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statutory tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "Tax computed at federal statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r224", "r476", "r496" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Tax benefits of corporate tax rate", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r1018", "r1023" ] }, "pkbo_EffectiveIncomeTaxRateReconciliationChangeInForeignJurisdictionTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationChangeInForeignJurisdictionTaxRate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction in Foreign Jurisdiction Tax Rate", "label": "Effective Income Tax Rate Reconciliation Change in Foreign Jurisdiction Tax Rate", "documentation": "Effective income tax rate reconciliation change in foreign jurisdiction tax rate" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings in jurisdictions taxed at rates different from the statutory U.S. federal tax rate", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r1018", "r1023" ] }, "pkbo_EffectiveIncomeTaxRateReconciliationPermanentDifferenceConvertibleNotes": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferenceConvertibleNotes", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Permanent difference related to change in fair value of convertible notes", "label": "Effective Income Tax Rate Reconciliation Permanent Difference Convertible Notes", "documentation": "Effective income tax rate reconciliation permanent difference convertible notes" } } }, "auth_ref": [] }, "pkbo_EffectiveIncomeTaxRateReconciliationPermanentDifferenceDerivatives": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferenceDerivatives", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Permanent difference related to change in fair value of derivatives", "label": "Effective Income Tax Rate Reconciliation Permanent Difference Derivatives", "documentation": "Effective income tax rate reconciliation permanent difference derivatives" } } }, "auth_ref": [] }, "pkbo_EffectiveIncomeTaxRateReconciliationPermanentDifferenceInterestExpenseOnConvertibleNotes": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferenceInterestExpenseOnConvertibleNotes", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Permanent difference related to interest expense on convertible notes", "label": "Effective Income Tax Rate Reconciliation Permanent Difference Interest Expense on Convertible Notes", "documentation": "Effective income tax rate reconciliation permanent difference interest expense on convertible notes" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefits of corporate tax rate", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense." } } }, "auth_ref": [ "r1018", "r1023" ] }, "pkbo_EffectiveIncomeTaxRateReconciliationReturnToProvision": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvision", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation, return to provision.", "label": "Effective Income Tax Rate Reconciliation Return to Provision", "terseLabel": "Return to Provision" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State Tax Provision/(Benefit) net of federal benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r1018", "r1023" ] }, "pkbo_EffectiveIncomeTaxRateReconciliationWarrantsIssuedOnConversion": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationWarrantsIssuedOnConversion", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxEffectiveRateDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation warrants issued on conversion.", "label": "Effective Income Tax Rate Reconciliation Warrants Issued on Conversion", "terseLabel": "Warrants issued on conversion" } } }, "auth_ref": [] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Embedded derivative fair value of derivative liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": [ "r87" ] }, "pkbo_EmployeeAndDirectorLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "EmployeeAndDirectorLoansMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee And Director Loans [Member]", "label": "Employee and Director Loans [Member]", "documentation": "Employee and Director Loans." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unvested stock-based compensation arrangements weighted average period of recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r460" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unvested stock-based compensation arrangements", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1017" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Common stock options [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "pkbo_EmploymentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "EmploymentAgreementMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employment Agreement [Member]", "documentation": "Employment agreement Member.", "label": "Employment Agreement [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r837" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r837" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r918" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r837" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r916" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r837" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r837" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r837" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r837" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well Known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r917" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficitParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r16", "r180", "r206", "r207", "r208", "r231", "r232", "r233", "r235", "r243", "r245", "r257", "r318", "r321", "r398", "r462", "r463", "r464", "r489", "r490", "r509", "r510", "r511", "r512", "r513", "r514", "r518", "r527", "r528", "r529", "r530", "r531", "r532", "r548", "r637", "r638", "r639", "r660", "r735" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r314", "r315", "r316" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Percentage of equity outstanding", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r314" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r884" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r847", "r859", "r869", "r895" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r844", "r856", "r866", "r892" ] }, "us-gaap_EscrowDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EscrowDeposit", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Escrow Deposit", "verboseLabel": "Escrow deposit", "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy." } } }, "auth_ref": [ "r96", "r770" ] }, "us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EscrowDepositDisbursementsRelatedToPropertyAcquisition1", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Escrow Deposit Disbursements Related to Property Acquisition", "verboseLabel": "Escrow deposit disbursements related to property acquisition", "documentation": "Amount of escrow deposit disbursements related to property acquisition in noncash investing or financing transactions." } } }, "auth_ref": [ "r52", "r53", "r54" ] }, "pkbo_ExchangeOfRelatedPartyLoansForConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ExchangeOfRelatedPartyLoansForConvertibleNotes", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange of related party loans for convertible notes, related party", "label": "Exchange Of Related Party Loans For Convertible Notes", "documentation": "Exchange of related party loans for convertible notes." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r890" ] }, "pkbo_ExerciseOfInvestorsRightToSellSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ExerciseOfInvestorsRightToSellSharesOfCommonStock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise of investor\u2019s right to sell shares of common stock.", "label": "Exercise of Investor's Right to Sell Shares of Common Stock", "verboseLabel": "Exercise of investor's right to sell shares of common stock" } } }, "auth_ref": [] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "settled the outstanding debt for a one-time payment", "label": "Extinguishment of Debt, Amount", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Change in fair value of warrant liability", "terseLabel": "Change in fair value of warrant liability", "negatedLabel": "Fair value of private warrants", "verboseLabel": "Less: fair value of redeemable warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r2", "r10" ] }, "pkbo_FairValueAdjustmentToDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueAdjustmentToDerivativeLiability", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of derivative liability", "documentation": "Fair value adjustment to derivative liability", "label": "Fair Value Adjustment Of Derivative Liability" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtTables", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Weighted Average Assumptions Used in Determining the Fair Value", "terseLabel": "Schedule of level 3 fair value measurements for private warrants", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r18" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Financial Instruments Measured at Fair Value on a Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r89", "r149" ] }, "pkbo_FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value assets transfers among level1 level2 and level3 amount.", "label": "Fair Value Assets Transfers Among Level1 Level2 and Level3 Amount", "terseLabel": "Transfers among the Level 1, Level 2 and Level 3 categories" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r366", "r414", "r415", "r416", "r417", "r418", "r419", "r522", "r564", "r565", "r566", "r800", "r801", "r812", "r813", "r814" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value of Financial Instruments", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r521" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices In Active Markets (Level 1) [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "verboseLabel": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r366", "r414", "r419", "r522", "r564", "r812", "r813", "r814" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r366", "r414", "r419", "r522", "r565", "r800", "r801", "r812", "r813", "r814" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Unobservable Inputs (Level 3) [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "verboseLabel": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r366", "r414", "r415", "r416", "r417", "r418", "r419", "r522", "r566", "r800", "r801", "r812", "r813", "r814" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of Warrants", "label": "Fair Value, Debt Instrument, Valuation Techniques, Change in Technique, Quantification of Effect", "documentation": "Represents the quantification of the effect of changes in the valuation technique and related inputs, during the period, used to measure the liability at fair value as of the statement of financial position reporting date." } } }, "auth_ref": [ "r18" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r19", "r90" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of warrant liability", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r523" ] }, "pkbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisBusinessCombinations": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisBusinessCombinations", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination with Ignyte", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Business Combinations", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis business combinations." } } }, "auth_ref": [] }, "pkbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisCapitalContributionUponExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisCapitalContributionUponExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Contribution from Exercise of Warrants", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Capital Contribution Upon Exercise of Warrants", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis capital contribution upon exercise of warrants." } } }, "auth_ref": [] }, "pkbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisCapitalContributionUponReclassificationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisCapitalContributionUponReclassificationOfWarrants", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Contribution from Reclassification of Warrants", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Capital Contribution Upon Reclassification of Warrants", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis capital contribution upon reclassification of warrants." } } }, "auth_ref": [] }, "pkbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDebtExtinguishment": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDebtExtinguishment", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Extinguishment of Debt", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Debt Extinguishment", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis debt extinguishment." } } }, "auth_ref": [] }, "pkbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisFairValueAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisFairValueAdjustments", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, fair value adjustments.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Fair Value Adjustments", "verboseLabel": "Change in fair value" } } }, "auth_ref": [] }, "pkbo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInceptionDate": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInceptionDate", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inception Date", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Inception Date", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis inception date." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair value measurement", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r19" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r366", "r414", "r415", "r416", "r417", "r418", "r419", "r564", "r565", "r566", "r800", "r801", "r812", "r813", "r814" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r19", "r25" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes In Level 3 Liabilities (Assets) Measured At Fair Value On Recurring Basis", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "verboseLabel": "Summary of Fair Value of Convertible Notes Payable, derivative liability, derivative asset and warrant liability Measured at Fair Value on Recurring Basis Determined Based on Significant Inputs Not Observable in Market", "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r19", "r25" ] }, "pkbo_FairValueOfDerivativeExcludingWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueOfDerivativeExcludingWarrants", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of derivative excluding warrants", "label": "Fair Value of Derivative Excluding Warrants", "documentation": "Fair Value of derivative excluding warrants." } } }, "auth_ref": [] }, "pkbo_FairValueOfForwardPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueOfForwardPurchaseAgreement", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of forward purchase agreement", "label": "Fair Value Of Forward Purchase Agreement", "documentation": "Fair value of forward purchase agreement." } } }, "auth_ref": [] }, "pkbo_FairValueOfPrivateWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueOfPrivateWarrants", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of private warrants", "negatedLabel": "Less: fair value of private warrants", "label": "Fair Value of Private Warrants", "documentation": "Fair Value of private Warrants" } } }, "auth_ref": [] }, "pkbo_FairValueOfWarrantsExercisedAndReclassifiedToAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueOfWarrantsExercisedAndReclassifiedToAdditionalPaidInCapital", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants exercised and reclassified to additional paid in capital", "label": "Fair Value Of Warrants Exercised And Reclassified To Additional Paid In Capital", "documentation": "Fair value of warrants exercised and reclassified to additional paid in capital." } } }, "auth_ref": [] }, "pkbo_FairValueOfWarrantsReclassifiedToAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FairValueOfWarrantsReclassifiedToAdditionalPaidInCapital", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants reclassified to additional paid in capital", "label": "Fair Value of Warrants Reclassified to Additional Paid in Capital", "documentation": "Fair value of warrants reclassified to additional paid in capital." } } }, "auth_ref": [] }, "us-gaap_FinancialGuaranteeInsuranceContractsPremiumReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialGuaranteeInsuranceContractsPremiumReceivable", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "periodStartLabel": "Financial Guarantee Insurance Contracts, Premium Receivable, Beginning Balance", "periodEndLabel": "Financial Guarantee Insurance Contracts, Premium Receivable, Ending Balance", "label": "Financial Guarantee Insurance Contracts, Premium Receivable", "terseLabel": "Total premiums, taxes and fees financed", "documentation": "Amount of the premium receivable for financial guarantee insurance contracts reported in the statement of financial position. This element primarily would consist of those financial guarantee insurance contracts which premiums are to be collected over the contract period, but may, on occasion, include premiums which are to be collected in full at inception, but which straddle a financial reporting period." } } }, "auth_ref": [ "r634", "r635" ] }, "us-gaap_FinancialGuaranteeInsuranceContractsPremiumReceivedOverContractPeriodPremiumReceivableWeightedAverageRiskFreeDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialGuaranteeInsuranceContractsPremiumReceivedOverContractPeriodPremiumReceivableWeightedAverageRiskFreeDiscountRate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "label": "Financial Guarantee Insurance Contracts, Premium Received over Contract Period, Premium Receivable, Weighted Average Risk Free Discount Rate", "terseLabel": "Annual interest rate", "documentation": "This element represents the weighted average risk free rate used to discount the premiums expected to be collected for financial guarantee insurance contracts where the premium is to be received over the contract period." } } }, "auth_ref": [ "r633" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r377", "r394", "r515", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r623", "r797", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r968", "r969", "r970", "r971" ] }, "pkbo_FinancingReceivedForAnnualInsurancePolicy": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FinancingReceivedForAnnualInsurancePolicy", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Financing received for annual insurance policy", "label": "Financing Received For Annual Insurance Policy", "terseLabel": "Financing received for annual insurance policy" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Authority [Member]", "terseLabel": "Korean", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r851", "r863", "r873", "r899" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r851", "r863", "r873", "r899" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r851", "r863", "r873", "r899" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r851", "r863", "r873", "r899" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r851", "r863", "r873", "r899" ] }, "pkbo_FormationCostMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FormationCostMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Formation Cost Member", "terseLabel": "Formation cost [Member]", "label": "FormationCostMember" } } }, "auth_ref": [] }, "pkbo_ForwardPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ForwardPurchaseAgreementMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Forward Purchase Agreement Member", "label": "Forward Purchase Agreement [Member]" } } }, "auth_ref": [] }, "pkbo_ForwardPurchaseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ForwardPurchaseAsset", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key company stockholder forward purchase asset.", "label": "Forward Purchase Asset", "documentation": "Forward purchase asset." } } }, "auth_ref": [] }, "pkbo_ForwardSharePurchaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ForwardSharePurchaseLiability", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Forward share purchase liability", "label": "Forward Share Purchase Liability", "terseLabel": "Less: forward share purchase liability assumed from Ignyte", "verboseLabel": "Forward share purchase liability" } } }, "auth_ref": [] }, "pkbo_ForwardSharePurchaseLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ForwardSharePurchaseLiabilityMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Share Purchase Liability [Member]", "label": "Forward Share Purchase Liability [Member]", "documentation": "Forward Share Purchase Liability." } } }, "auth_ref": [] }, "pkbo_FounderAndDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FounderAndDirectorMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Founder and director.", "label": "Founder and Director[ Member]", "terseLabel": "Founder and Director[ Member]" } } }, "auth_ref": [] }, "pkbo_FounderAndDirectorWarrantsSubscriptionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FounderAndDirectorWarrantsSubscriptionAgreementMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Founder And Director Warrants Subscription Agreement [Member]", "documentation": "Founder And Director Warrants Subscription Agreement [Member]" } } }, "auth_ref": [] }, "pkbo_FounderLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FounderLoansMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Founder Loans [Member]", "label": "Founder Loans [Member]", "documentation": "Founder loans." } } }, "auth_ref": [] }, "pkbo_FounderSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FounderSharesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Founder Shares Member", "terseLabel": "Founder Shares [Member]", "label": "FounderSharesMember" } } }, "auth_ref": [] }, "pkbo_FrostGammaInvestmentsTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "FrostGammaInvestmentsTrustMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Frost Gamma Investments Trust Member", "label": "Frost Gamma Investments Trust [Member]" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of derivative liability", "terseLabel": "Change in fair value of derivative liability", "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "totalLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax, Total", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r85" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on disposal of equipment", "terseLabel": "Loss on disposal of equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r10" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on extinguishment of debt", "verboseLabel": "Gain on debt extinguishment", "negatedLabel": "Loss on extinguishment of debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r10", "r66", "r67" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r120", "r714" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General And Administrative Expense [Member]", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r119" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Goodwill, Total", "periodStartLabel": "Goodwill, Beginning Balance", "periodEndLabel": "Goodwill, Ending Balance", "label": "Goodwill", "terseLabel": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r188", "r332", "r605", "r798", "r823", "r975", "r976" ] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Grant [Member]", "terseLabel": "Grant revenue", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r990" ] }, "pkbo_GrossProceedsPercentange": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "GrossProceedsPercentange", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Gross proceeds percentage", "label": "Gross Proceeds Percentange", "documentation": "Gross proceeds percentange." } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPO [Member]", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r841", "r842", "r855" ] }, "pkbo_IgnyteFounderShares1": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IgnyteFounderShares1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNumberOfSharesOfCommonStockIssuedImmediatelyFollowingTheConsummationOfTheBusine" ], "lang": { "en-us": { "role": { "terseLabel": "Ignyte founder shares", "label": "Ignyte Founder Shares 1", "documentation": "Ignyte founder shares." } } }, "auth_ref": [] }, "pkbo_IgnyteSponsorLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IgnyteSponsorLLCMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails" ], "lang": { "en-us": { "role": { "documentation": "Ignyte Sponsor L L C Member", "terseLabel": "Ignyte Sponsor LLC [Member]", "label": "IgnyteSponsorLLCMember" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r133" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r223", "r495" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income tax expense", "verboseLabel": "(Loss) income before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income tax expense", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r117", "r156", "r260", "r272", "r276", "r278", "r608", "r620", "r794" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r223", "r495" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r333", "r334", "r719" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r334", "r719" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r224", "r472", "r477", "r479", "r486", "r491", "r497", "r498", "r499", "r655" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax benefit", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense", "verboseLabel": "(Benefit from) provision for income taxes", "totalLabel": "(Benefit from) provision for income taxes", "negatedLabel": "Income tax expense (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r161", "r174", "r244", "r245", "r264", "r475", "r492", "r626" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r205", "r473", "r474", "r479", "r480", "r485", "r487", "r649" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in Valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r1018" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid", "terseLabel": "Cash paid for taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r48", "r51" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInNotesPayableCurrent", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Notes Payable, Current, Total", "label": "Increase (Decrease) in Notes Payable, Current", "terseLabel": "Convertible note payable", "verboseLabel": "Change in the fair value of the promissory notes", "documentation": "The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r927", "r949" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Assets", "terseLabel": "Other noncurrent assets", "negatedLabel": "Other noncurrent assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r949" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r9" ] }, "pkbo_IncreaseDecreaseInaccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IncreaseDecreaseInaccruedExpensesAndOtherCurrentLiabilities", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Increase decrease inaccrued expenses and other current liabilities.", "label": "Increase Decrease InAccrued Expenses and Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "pkbo_IncrementalBorrowingRate": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IncrementalBorrowingRate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental borrowing rate.", "label": "Incremental Borrowing Rate", "terseLabel": "Incremental borrowing rate" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r854", "r863", "r873", "r890", "r899", "r903", "r911" ] }, "pkbo_IngallsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IngallsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Ingalls Member", "label": "Ingalls [Member]" } } }, "auth_ref": [] }, "pkbo_InitialCommitmentShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "InitialCommitmentShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial commitment shares.", "label": "Initial Commitment Shares", "terseLabel": "Initial commitment shares" } } }, "auth_ref": [] }, "pkbo_InitialPublicOfferingDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "InitialPublicOfferingDetailsLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering Details Line Items", "label": "Initial Public Offering (Details) [Line Items]" } } }, "auth_ref": [] }, "pkbo_InitialPublicOfferingDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "InitialPublicOfferingDetailsTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering Details Table", "label": "Initial Public Offering (Details) [Table]" } } }, "auth_ref": [] }, "pkbo_InitialTermOfResearchCollaboration": { "xbrltype": "durationItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "InitialTermOfResearchCollaboration", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial term of research collaboration.", "label": "Initial Term Of Research Collaboration", "terseLabel": "Initial term of collaboration" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r909" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r843", "r915" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r843", "r915" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r843", "r915" ] }, "pkbo_InsuranceFinancingNote": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "InsuranceFinancingNote", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance financing note", "label": "Insurance Financing Note", "documentation": "Insurance Financing Note" } } }, "auth_ref": [] }, "pkbo_InsuranceFinancingPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "InsuranceFinancingPayable", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "documentation": "Insurance financing payable.", "label": "Insurance Financing Payable", "terseLabel": "Insurance financing payable" } } }, "auth_ref": [] }, "pkbo_InsuranceFinancingPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "InsuranceFinancingPayableMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Financing Note [Member]", "label": "Insurance Financing Payable [Member]", "documentation": "Insurance financing payable." } } }, "auth_ref": [] }, "us-gaap_InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndOtherIncome", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest and Other Income", "terseLabel": "Interest income", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Interest Expense, Total", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r93", "r160", "r209", "r263", "r534", "r720", "r834", "r1057" ] }, "us-gaap_InterestExpenseLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseLongTermDebt", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Due", "label": "Interest Expense, Long-Term Debt", "totalLabel": "Interest Expense, Long-Term Debt, Total", "documentation": "Aggregate amount of interest paid or due on all long-term debt." } } }, "auth_ref": [ "r159", "r178", "r179" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r213", "r216", "r217" ] }, "pkbo_Interestpercentageoftenantimprovements": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "Interestpercentageoftenantimprovements", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "InterestPercentageOfTenantImprovements", "label": "InterestPercentageOfTenantImprovements", "terseLabel": "Interest Percentage of Tenant Improvements" } } }, "auth_ref": [] }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalancePrincipalAmount", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Investment Owned, Balance, Principal Amount", "terseLabel": "Principal amount", "documentation": "Amount of principal of investment owned." } } }, "auth_ref": [ "r672", "r680", "r744", "r750", "r760", "r828" ] }, "us-gaap_InvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestorMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Investor [Member]", "terseLabel": "Investor [Member]", "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value." } } }, "auth_ref": [ "r1034", "r1035" ] }, "pkbo_IssuanceOfCommonStockUnderWhiteLionPurchaseAgreementAsAFinancingFee": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfCommonStockUnderWhiteLionPurchaseAgreementAsAFinancingFee", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under White Lion Purchase Agreement as a financing fee", "label": "Issuance of Common Stock under White Lion Purchase Agreement as a Financing Fee", "documentation": "Issuance of Common stock under White Lion Purchase Agreement as a financing fee" } } }, "auth_ref": [] }, "pkbo_IssuanceOfCommonStockUnderWhiteLionPurchaseAgreementAsAFinancingFeeShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfCommonStockUnderWhiteLionPurchaseAgreementAsAFinancingFeeShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Common Stock under White Lion Purchase Agreement as a financing fee, shares", "label": "Issuance of Common Stock under White Lion Purchase Agreement as a Financing Fee Shares", "documentation": "Issuance of Common stock under White Lion Purchase Agreement as a financing fee shares" } } }, "auth_ref": [] }, "pkbo_IssuanceOfCommonStockUponExerciseOfConvertibleNoteWarrantsFromLiabilityToEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfCommonStockUponExerciseOfConvertibleNoteWarrantsFromLiabilityToEquity", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of April 2023 Convertible Note Warrants", "label": "Issuance of Common Stock upon Exercise of Convertible Note Warrants from Liability to Equity", "documentation": "Issuance of common stock upon exercise of convertible note warrants from liability to equity." } } }, "auth_ref": [] }, "pkbo_IssuanceOfCommonStockUponExerciseOfConvertibleNoteWarrantsFromLiabilityToEquityShare": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfCommonStockUponExerciseOfConvertibleNoteWarrantsFromLiabilityToEquityShare", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of April 2023 Convertible Note Warrants, share", "label": "Issuance of Common Stock upon Exercise of Convertible Note Warrants from Liability to Equity Share", "documentation": "Issuance of common stock upon exercise of convertible note warrants from liability to equity share." } } }, "auth_ref": [] }, "pkbo_IssuanceOfCommonStockUponExerciseOfPipeWarrantsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfCommonStockUponExerciseOfPipeWarrantsAmount", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of PIPE Warrants", "label": "Issuance of Common Stock upon Exercise of PIPE Warrants Amount", "documentation": "Issuance of common stock upon exercise of PIPE warrants amount." } } }, "auth_ref": [] }, "pkbo_IssuanceOfCommonStockUponExerciseOfPipeWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfCommonStockUponExerciseOfPipeWarrantsShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of PIPE Warrants, shares", "label": "Issuance of Common Stock upon Exercise of PIPE Warrants Shares", "documentation": "Issuance of common stock upon exercise of PIPE warrants shares" } } }, "auth_ref": [] }, "pkbo_IssuanceOfCommonStockUponExerciseOfWarrantAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfCommonStockUponExerciseOfWarrantAmount", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of warrants, amount", "label": "Issuance Of Common Stock Upon Exercise Of Warrant Amount", "documentation": "Issuance of common stock upon exercise of warrant amount." } } }, "auth_ref": [] }, "pkbo_IssuanceOfCommonStockUponExerciseOfWarrantShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfCommonStockUponExerciseOfWarrantShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of warrants, shares", "label": "Issuance Of Common Stock Upon Exercise Of Warrant Shares", "documentation": "Issuance of common stock upon exercise of warrant shares." } } }, "auth_ref": [] }, "pkbo_IssuanceOfPipeShares": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfPipeShares", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of PIPE Shares", "label": "Issuance of PIPE Shares", "documentation": "Issuance of PIPE shares." } } }, "auth_ref": [] }, "pkbo_IssuanceOfSharesForDebtSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfSharesForDebtSettlement", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Issuance of shares for debt settlement.", "label": "Issuance of Shares for Debt Settlement", "terseLabel": "Issuance of Shares for Debt Settlement" } } }, "auth_ref": [] }, "pkbo_IssuanceOfSharesForDebtSettlementShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfSharesForDebtSettlementShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase and retirement of share under Forward Share Purchase Agreement", "documentation": "Issuance of shares for debt settlement shares.", "label": "Issuance of Shares for Debt Settlement Shares", "terseLabel": "Issuance of Shares for Debt Settlement, shares" } } }, "auth_ref": [] }, "pkbo_IssuanceOfSharesForFinancingFee": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfSharesForFinancingFee", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Issuance of shares for financing fee.", "label": "Issuance of Shares for Financing Fee", "terseLabel": "Issuance of shares for financing fee" } } }, "auth_ref": [] }, "pkbo_IssuanceOfSharesForFinancingFeeShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfSharesForFinancingFeeShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Issuance of shares for financing fee, shares.", "label": "Issuance Of Shares For Financing Fee, Shares", "terseLabel": "Issuance Of Shares For Financing Fee, shares" } } }, "auth_ref": [] }, "pkbo_IssuanceOfSharesToPipeSubscribers": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "IssuanceOfSharesToPipeSubscribers", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of PIPE Warrants , Value", "label": "Issuance of Shares to PIPE Subscribers", "documentation": "Issuance of shares to PIPE subscribers." } } }, "auth_ref": [] }, "pkbo_KeyCompanyStockholderForwardLiabilityAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "KeyCompanyStockholderForwardLiabilityAssetMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Key Company Stockholder Forward Liability (Asset) [Member]", "label": "Key Company Stockholder Forward Liability Asset [Member]", "documentation": "Key Company Stockholder Forward Liability Asset." } } }, "auth_ref": [] }, "pkbo_KeyCompanyStockholderForwardPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "KeyCompanyStockholderForwardPurchaseAgreementMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Key company stockholder forward purchase agreement.", "label": "Key Company Stockholder Forward Purchase Agreement [Member]", "terseLabel": "Key Company Stockholder Forward Purchase Agreement [Member]" } } }, "auth_ref": [] }, "pkbo_KnightFamilyMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "KnightFamilyMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Knight Family Member", "label": "Knight Family [Member]" } } }, "auth_ref": [] }, "pkbo_LabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "LabEquipmentMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Lab equipment.", "label": "Lab Equipment [Member]" } } }, "auth_ref": [] }, "pkbo_LastSalePriceOfCommonStock": { "xbrltype": "perShareItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "LastSalePriceOfCommonStock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Last sale price of Common Stock", "label": "LastSalePriceOfCommonStock", "documentation": "Last sale price of common stock." } } }, "auth_ref": [] }, "pkbo_LeaseExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "LeaseExpirationMonthAndYear", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease expiration month and year.", "label": "Lease Expiration Month and Year", "terseLabel": "Lease expiration month and year" } } }, "auth_ref": [] }, "pkbo_LeaseExpirationPeriod": { "xbrltype": "gYearMonthItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "LeaseExpirationPeriod", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease expiration period.", "label": "Lease Expiration Period", "verboseLabel": "Lease expiration period" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r132" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "pkbo_LeasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "LeasesLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Leases.", "label": "Leases [Line Items]" } } }, "auth_ref": [] }, "pkbo_LeasesTable": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "LeasesTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Leases.", "label": "Leases [Table]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r541" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "verboseLabel": "Summary of Future Lease Payments under Noncancelable Leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1031" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureLeasePaymentsUnderNoncancelableLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r546" ] }, "pkbo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureLeasePaymentsUnderNoncancelableLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "documentation": "Lessee operating lease liability payments due after year four." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureLeasePaymentsUnderNoncancelableLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureLeasePaymentsUnderNoncancelableLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureLeasePaymentsUnderNoncancelableLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureLeasePaymentsUnderNoncancelableLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureLeasePaymentsUnderNoncancelableLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "verboseLabel": "Less: imputed interest", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r546" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "verboseLabel": "Lessee, operating lease, renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1030" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeases3" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r537" ] }, "pkbo_LetterAgreementForConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "LetterAgreementForConversion", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter agreement for conversion", "label": "Letter Agreement for Conversion", "documentation": "Letter agreement for conversion." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r32", "r222", "r317", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r504", "r507", "r508", "r525", "r689", "r793", "r836", "r984", "r1038", "r1039" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities [Abstract]", "verboseLabel": "Liabilities Assumed" } } }, "auth_ref": [] }, "pkbo_LiabilitiesAndStockholdersDeficitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "LiabilitiesAndStockholdersDeficitAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Liabilities And Stockholders Deficit Abstract", "terseLabel": "Liabilities and Stockholders' Deficit", "label": "LiabilitiesAndStockholdersDeficitAbstract" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r113", "r155", "r616", "r823", "r954", "r972", "r1028" ] }, "pkbo_LiabilitiesAssumed2": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "LiabilitiesAssumed2", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Liabilities assumed", "label": "Liabilities Assumed 2", "documentation": "Liabilities Assumed 2" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r34", "r184", "r222", "r317", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r504", "r507", "r508", "r525", "r823", "r984", "r1038", "r1039" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of convertible notes", "label": "Liabilities, Fair Value Adjustment", "verboseLabel": "Fair value adjustment to long-term convertible notes payable", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "pkbo_Liabilityforpromissorynote": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "Liabilityforpromissorynote", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability for the promissory note", "label": "LiabilityForPromissoryNote", "documentation": "Liability for promissory note." } } }, "auth_ref": [] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans Payable [Member]", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "us-gaap_LoansPayableToBank": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableToBank", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Loans Payable to Bank, Total", "label": "Loans Payable to Bank", "terseLabel": "Loans Payable to Bank", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the normal operating cycle if longer." } } }, "auth_ref": [ "r28", "r154", "r1049" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Long-Term Debt, Total", "label": "Long-Term Debt", "terseLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r28", "r154", "r365", "r379", "r800", "r801", "r1049" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r37" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r37", "r64" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r337", "r338", "r339", "r342", "r979", "r980" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyNatureDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r337", "r338", "r339", "r342", "r979", "r980" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r282", "r807", "r989", "r1051", "r1052" ] }, "pkbo_MarchTwothousandTwentyThreeFounderLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "MarchTwothousandTwentyThreeFounderLoanMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "March 2023 Founder Loan [Member]", "label": "March TwoThousand Twenty Three Founder Loan [Member]", "documentation": "March 2023 Founder Loan." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "auth_ref": [ "r338", "r339", "r340", "r341", "r421", "r591", "r636", "r681", "r682", "r743", "r746", "r748", "r749", "r759", "r781", "r782", "r796", "r804", "r817", "r825", "r988", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045" ] }, "pkbo_May2024ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "May2024ConvertibleNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "May 2024 Convertible Notes", "label": "May 2024 Convertible Notes [Member]", "documentation": "May 2024 convertible notes." } } }, "auth_ref": [] }, "pkbo_MayTwentyTwentyTwoCommonStockIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "MayTwentyTwentyTwoCommonStockIssuanceMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "May 2022 Common Stock Issuance [Member]", "label": "May Twenty Twenty Two Common Stock Issuance [Member]", "documentation": "May twenty twenty two common stock issuance." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r882" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r882" ] }, "pkbo_MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "MergerAgreementExpectedOwnershipInCompanyCounterpartyStockholdersPercentage", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of expected ownership in outstanding shares", "label": "Merger Agreement Expected Ownership in Company Counterparty Stockholders Percentage", "documentation": "Merger agreement expected ownership in company counterparty stockholders percentage." } } }, "auth_ref": [] }, "pkbo_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "MilestonePayments", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments" } } }, "auth_ref": [] }, "pkbo_MilestonesPaymentAggregateAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "MilestonesPaymentAggregateAmount", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestones aggregate amount", "label": "Milestones Payment Aggregate Amount", "documentation": "Milestones payment aggregate amount." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [ "r338", "r339", "r340", "r341", "r421", "r591", "r636", "r681", "r682", "r743", "r746", "r748", "r749", "r759", "r781", "r782", "r796", "r804", "r817", "r825", "r988", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045" ] }, "pkbo_MinimumRequirementOfSharesHeldByShareholders": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "MinimumRequirementOfSharesHeldByShareholders", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum requirement of shares held by shareholders", "label": "Minimum Requirement of Shares Held by Shareholders", "documentation": "Minimum requirement of shares held by shareholders." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r902" ] }, "pkbo_MortgageLoansOnRealEstatesDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "MortgageLoansOnRealEstatesDescriptionTypeOfPropertyAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estates Description Type Of Property Axis", "label": "Mortgage Loans on Real Estates Description Type of Property [Axis]" } } }, "auth_ref": [] }, "pkbo_MortgageLoansOnRealEstatesDescriptionTypeOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "MortgageLoansOnRealEstatesDescriptionTypeOfPropertyDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Mortgage Loans On Real Estates Description Type Of Property Domain", "terseLabel": "Mortgage Loans on Real Estates Description Type of Property [Domain]", "label": "MortgageLoansOnRealEstatesDescriptionTypeOfProperty [Domain]" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r910" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r282", "r807", "r989", "r1051", "r1052" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r883" ] }, "pkbo_NetAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "NetAssetsAcquired", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net assets acquired", "label": "Net Assets Acquired", "documentation": "Net assets acquired" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r215" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r215" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r125", "r126", "r127" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r118", "r127", "r157", "r182", "r201", "r203", "r208", "r222", "r234", "r236", "r237", "r239", "r240", "r244", "r245", "r251", "r260", "r272", "r276", "r278", "r317", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r520", "r525", "r622", "r711", "r733", "r734", "r794", "r834", "r984" ] }, "pkbo_NetInvestmentFromParent": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "NetInvestmentFromParent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Net investment from parent.", "label": "Net Investment from Parent", "terseLabel": "Net investment from parent" } } }, "auth_ref": [] }, "pkbo_NetOperatingLossGeneratedAfterTwentyTwentyCarryforwardTerm": { "xbrltype": "durationItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "NetOperatingLossGeneratedAfterTwentyTwentyCarryforwardTerm", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Net operating loss generated after 2020 carryforward term.", "label": "Net Operating Loss Generated After Twenty Twenty Carryforward Term", "terseLabel": "NOLs generated after 2020, carryforward term" } } }, "auth_ref": [] }, "pkbo_NetOperatingLossGeneratedPriorToTwentyTwentyCarryforwardTerm": { "xbrltype": "durationItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "NetOperatingLossGeneratedPriorToTwentyTwentyCarryforwardTerm", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Net operating loss generated prior to 2020 carryforward term.", "label": "Net Operating Loss Generated Prior to Twenty Twenty Carryforward Term", "terseLabel": "NOLs generated before 2020, carryforward term" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted and Issued Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "pkbo_NewSubscriberMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "NewSubscriberMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "New subscriber.", "label": "New Subscriber [Member]" } } }, "auth_ref": [] }, "pkbo_NonCashTransactionCostsAllocatedToTheCompanysEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "NonCashTransactionCostsAllocatedToTheCompanysEquity", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Less: transaction costs allocated to the Company's equity", "label": "Non Cash Transaction Costs Allocated to the Company's Equity", "documentation": "Noncash transaction costs allocated to the company's equity" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r882" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r851", "r863", "r873", "r890", "r899" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r880" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r879" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r890" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r910" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r910" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionDebtAssumed1", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Debt Assumed", "terseLabel": "Related party loan assumed in Business Combination", "documentation": "The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r52", "r53", "r54" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed, Total", "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed", "terseLabel": "Warrant liability assumed in Business Combination", "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r52", "r53", "r54" ] }, "us-gaap_NoninterestExpenseCommissionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoninterestExpenseCommissionExpense", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Cash commission", "label": "Noninterest Expense Commission Expense", "documentation": "Amount of fees incurred for commissions on mutual funds and insurance products." } } }, "auth_ref": [ "r158" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r121" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense)" } } }, "auth_ref": [] }, "us-gaap_NonrecurringAdjustmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrecurringAdjustmentAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashFlowsRelatedBusinessCombinationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail" ], "lang": { "en-us": { "role": { "label": "Nonrecurring Adjustment [Axis]", "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_NonrecurringAdjustmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrecurringAdjustmentDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashFlowsRelatedBusinessCombinationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail" ], "lang": { "en-us": { "role": { "label": "Nonrecurring Adjustment [Domain]", "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrelated Party [Member]", "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r956", "r957" ] }, "pkbo_November2022ConvertibleNoteLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "November2022ConvertibleNoteLiabilityMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "November 2022 Convertible Note Liability [Member]", "label": "November 2022 Convertible Note Liability [Member]", "documentation": "November 2022 Convertible Note Liability." } } }, "auth_ref": [] }, "pkbo_November2022ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "November2022ConvertibleNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "November 2022 Convertible Notes [Member]", "label": "November 2022 Convertible Notes [Member]", "documentation": "November 2022 Convertible Notes." } } }, "auth_ref": [] }, "pkbo_NumberOfBusinessDaysToRepurchaseSharesFromTheClosingOfTheBusinessCombination": { "xbrltype": "durationItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "NumberOfBusinessDaysToRepurchaseSharesFromTheClosingOfTheBusinessCombination", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of business days to repurchase shares from the closing of the Business Combination", "label": "Number Of Business Days To Repurchase Shares From The Closing Of The Business Combination", "documentation": "Number of business days to repurchase shares from the closing of the Business Combination." } } }, "auth_ref": [] }, "pkbo_NumberOfDerivativesRemains": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "NumberOfDerivativesRemains", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of derivatives remains", "label": "Number of Derivatives Remains", "documentation": "Number of derivatives remains." } } }, "auth_ref": [] }, "pkbo_NumberOfEmployees": { "xbrltype": "integerItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "NumberOfEmployees", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of employees.", "label": "Number Of Employees", "terseLabel": "Number of employees" } } }, "auth_ref": [] }, "pkbo_NumberOfFounderSharesAreNoLongerSubjectToForfeitureSinceIpo": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "NumberOfFounderSharesAreNoLongerSubjectToForfeitureSinceIpo", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Founder Shares are no longer subject to forfeiture since IPO", "label": "NumberOfFounderSharesAreNoLongerSubjectToForfeitureSinceIpo", "documentation": "Number of Founder Shares are no longer subject to forfeiture since IPO." } } }, "auth_ref": [] }, "pkbo_NumberOfMilestonesAchieved": { "xbrltype": "integerItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "NumberOfMilestonesAchieved", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of milestones achieved", "label": "Number of Milestones Achieved", "documentation": "Number of milestones achieved." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segment", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r966" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reporting segment", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r966" ] }, "pkbo_OfficeSpaceUtilitiesAndSecretarialSupportMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "OfficeSpaceUtilitiesAndSecretarialSupportMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Office Space Utilities And Secretarial Support Member", "terseLabel": "Office space, utilities and secretarial support [Member]", "label": "OfficeSpaceUtilitiesAndSecretarialSupportMember" } } }, "auth_ref": [] }, "srt_OfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OfficerMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Officer [Member]", "label": "Officer [Member]" } } }, "auth_ref": [ "r283", "r1055" ] }, "us-gaap_OpenTaxYear": { "xbrltype": "gYearListItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OpenTaxYear", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Open Tax Year", "terseLabel": "Open tax year", "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format." } } }, "auth_ref": [ "r478" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r260", "r272", "r276", "r278", "r794" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss on operating right-of-use asset", "negatedLabel": "Impairment loss on operating lease right-of-use asset", "label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1029" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfFutureLeasePaymentsUnderNoncancelableLeasesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liability", "label": "Operating Lease, Liability", "totalLabel": "Total future minimum lease payments", "terseLabel": "Total future minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r539" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current", "verboseLabel": "Right of Use Operating Lease ASC 842", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r539" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease, liability, noncurrent", "terseLabel": "Operating lease liability, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r539" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfQuantitativeInformationRegardingCompanysLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "verboseLabel": "Operating cash flows paid for amounts included in the measurement of lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r540", "r542" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset", "verboseLabel": "Right of Use Operating Lease ASC 842", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r538" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Amortization of right-of-use lease asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r950" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfQuantitativeInformationRegardingCompanysLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r545", "r822" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfQuantitativeInformationRegardingCompanysLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "verboseLabel": "Weighted-average remaining lease terms (years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r544", "r822" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r78" ] }, "pkbo_OperatingLossCarryforwardsExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "OperatingLossCarryforwardsExpirationYear", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards, expiration year.", "label": "Operating Loss Carryforwards Expiration Year", "terseLabel": "Operating loss carryforwards expiration year" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r77" ] }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsValuationAllowance", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards, Valuation Allowance", "terseLabel": "Net operating losses deduction in valuation allowance", "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r76" ] }, "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityStrikePrice1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Strike Price", "terseLabel": "Common stock per share", "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares." } } }, "auth_ref": [ "r22", "r27" ] }, "pkbo_OptionalConversionFeatureMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "OptionalConversionFeatureMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Optional Conversion Feature [Member]", "label": "Optional Conversion Feature [Member]", "documentation": "Optional conversion feature." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "pkbo_OrganizationandBusinessOperationsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "OrganizationandBusinessOperationsDetailsLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Organizationand Business Operations Details Line Items", "label": "Organization and Business Operations (Details) [Line Items]" } } }, "auth_ref": [] }, "pkbo_OrganizationandBusinessOperationsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "OrganizationandBusinessOperationsDetailsTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Organization and Business Operations [Table]", "label": "Organization and Business Operations (Details) [Table]" } } }, "auth_ref": [] }, "pkbo_OriginalPipeSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "OriginalPipeSharesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Original PIPE Shares.", "label": "Original PIPE Shares [Member]" } } }, "auth_ref": [] }, "pkbo_OriginalSubscriberMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "OriginalSubscriberMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Original subscriber.", "label": "Original Subscriber [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "terseLabel": "Accrued expenses", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r33" ] }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Accrued Liabilities Noncurrent", "label": "Other Accrued Liabilities Noncurrent", "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r38" ] }, "pkbo_OtherAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "OtherAssets1", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets1", "documentation": "Other Assets1" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r189" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r7", "r14", "r148" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Total", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "terseLabel": "Foreign currency translation", "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5", "r116" ] }, "pkbo_OtherIncomePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "OtherIncomePolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other Income", "label": "Other Income [Policy Text Block]", "documentation": "Other income." } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other Intangible Assets, Net", "terseLabel": "Other intangible assets", "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other." } } }, "auth_ref": [] }, "pkbo_OtherLiabilitiesAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "OtherLiabilitiesAndAccruedExpenses", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities and accrued expenses", "label": "Other Liabilities and Accrued Expenses", "documentation": "Other liabilities and accrued expenses" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r38" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "totalLabel": "OtherNonoperatingIncomeExpense", "terseLabel": "Other income", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r123" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r882" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsScheduleOfPrepaidAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables, Net, Current", "totalLabel": "Other Receivables, Net, Current, Total", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "pkbo_OtherWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "OtherWarrantsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other warrants.", "label": "Other Warrants [Member]", "terseLabel": "Other Warrants [Member]" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r849", "r861", "r871", "r897" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r852", "r864", "r874", "r900" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r852", "r864", "r874", "r900" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OverAllotmentOptionMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Units [Member]", "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "pkbo_PaloAltoCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PaloAltoCaliforniaMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Palo Alto, California.", "label": "Palo Alto, California [Member]" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company [Member]", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r878" ] }, "pkbo_PaymentOfCommission": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PaymentOfCommission", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment of Commission", "label": "Payment of Commission", "terseLabel": "Commission paid" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Rent", "verboseLabel": "Base rent for sublease", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PaymentsForTenantImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForTenantImprovements", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Tenant Improvements", "terseLabel": "Payments for Tenant Improvements", "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy." } } }, "auth_ref": [] }, "us-gaap_PaymentsForUnderwritingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForUnderwritingExpense", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Underwriting fees (in Dollars)", "terseLabel": "Payment of underwriting discount", "label": "Payments for Underwriting Expense", "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "label": "Payments to Acquire Property, Plant, and Equipment", "terseLabel": "Purchase of property and equipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r124" ] }, "pkbo_PeakBioCompanyLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PeakBioCompanyLimitedMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "documentation": "Peak Bio Company Limited Member", "label": "Peak Bio Company Limited [Member]" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r881" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r881" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r880" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r890" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r883" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r879" ] }, "pkbo_PercentageOfAccruedUnpaidPrincipalBalances": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PercentageOfAccruedUnpaidPrincipalBalances", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of accrued unpaid principal balances.", "label": "Percentage Of Accrued Unpaid Principal Balances", "terseLabel": "Unpaid principal balance rate" } } }, "auth_ref": [] }, "pkbo_PercentageOfDailyVolumeWeightedAveragePriceOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PercentageOfDailyVolumeWeightedAveragePriceOfCommonStock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of daily volume-weighted average price of common stock", "label": "Percentage Of Daily Volume-weighted Average Price Of Common Stock", "documentation": "Percentage of daily volume-weighted average price of common stock." } } }, "auth_ref": [] }, "pkbo_PercentageOfDiscountAwardedUponConversion": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PercentageOfDiscountAwardedUponConversion", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of Discount Awarded upon Conversion", "label": "Percentage of Discount Awarded upon Conversion", "terseLabel": "Percentage of Discount Awarded upon Conversion" } } }, "auth_ref": [] }, "pkbo_PercentageOfDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PercentageOfDiscountRate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Discount related to the probability of timely filing all SEC documents and meeting the NASDAQ listing requirements", "documentation": "Percentage of discount rate.", "label": "Percentage of Discount Rate", "terseLabel": "Percentage of Discount Rate" } } }, "auth_ref": [] }, "pkbo_PercentageOfEstimatedProbabilityOfMaturity": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PercentageOfEstimatedProbabilityOfMaturity", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of estimated probability of maturity.", "label": "Percentage of Estimated Probability of Maturity", "terseLabel": "Percentage of Estimated Probability of Maturity" } } }, "auth_ref": [] }, "pkbo_PercentageOfRelatedPartyLoan": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PercentageOfRelatedPartyLoan", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of related party loan.", "label": "Percentage of Related Party Loan", "terseLabel": "Percentage of related party loan" } } }, "auth_ref": [] }, "pkbo_PercentageOfSharesOwnedByStockholdersInIssuedAndOutstandingCommonStockAfterIpo": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PercentageOfSharesOwnedByStockholdersInIssuedAndOutstandingCommonStockAfterIpo", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of shares owned by stockholders in issued and outstanding common stock after IPO", "label": "PercentageOfSharesOwnedByStockholdersInIssuedAndOutstandingCommonStockAfterIpo", "documentation": "Percentage of shares owned by stockholders in issued and outstanding common stock after IPO." } } }, "auth_ref": [] }, "pkbo_PercentageOfTheTotalNumberOfSharesOfCommonStockReceived": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PercentageOfTheTotalNumberOfSharesOfCommonStockReceived", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of the total number of shares of common stock received", "label": "Percentage of The Total Number of Shares of Common Stock Received", "documentation": "Percentage of the total number of shares of common stock received." } } }, "auth_ref": [] }, "pkbo_PhPharmaCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PhPharmaCoLtdMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "PH Pharma Co Ltd.", "label": "PH Pharma Co Ltd [Member]", "terseLabel": "pH Pharma Co., Ltd" } } }, "auth_ref": [] }, "pkbo_PhPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PhPharmaIncMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "pH Pharma, Inc. member.", "label": "pH Pharma, Inc. [Member]", "terseLabel": "pH Pharma, Inc. [Member]" } } }, "auth_ref": [] }, "pkbo_PhPharmaLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PhPharmaLtdMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails" ], "lang": { "en-us": { "role": { "documentation": "PH Pharma Ltd.", "label": "PH Pharma Ltd [Member]", "terseLabel": "pH Pharma Ltd" } } }, "auth_ref": [] }, "pkbo_PipeFinancingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PipeFinancingWarrantsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Pipe Financing Warrants Member", "label": "PIPE Financing Warrants [Member]" } } }, "auth_ref": [] }, "pkbo_PipeSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PipeSharesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Pipe Shares Member", "label": "PIPE Shares [Member]" } } }, "auth_ref": [] }, "pkbo_PipeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PipeWarrantsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PIPE Warrants [Member]", "documentation": "PIPE warrants.", "label": "PIPE Warrants [Member]" } } }, "auth_ref": [] }, "pkbo_PreBusinessCombinationConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PreBusinessCombinationConvertibleNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Pre-Business Combination Convertible Notes [Member]", "label": "2022 Pre-Business Combination Convertible Notes [Member]", "documentation": "2022 Pre-Business Combination Convertible Notes." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheetsParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, par value (in Dollars per share)", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r107", "r382" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheetsParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Preference shares, shares authorized", "terseLabel": "Preferred Stock, Shares Authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r107", "r691" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheetsParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Issued", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r107", "r382" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheetsParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, Shares Outstanding", "label": "Preferred Stock, Shares Outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r107", "r691", "r709", "r1058", "r1059" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r107", "r612", "r823" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsScheduleOfPrepaidAndOtherCurrentAssetsDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Prepaid Expense and other current assets", "terseLabel": "Prepaid Expense and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r943" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsScheduleOfPrepaidAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "totalLabel": "Prepaid Expense, Current, Total", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r195", "r330", "r331", "r787" ] }, "pkbo_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and Other Current Assets", "label": "Prepaid Expenses And Other Current Assets [Policy Text Block]", "documentation": "Prepaid expenses and other current assets." } } }, "auth_ref": [] }, "pkbo_PrivatePlacementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PrivatePlacementAbstract", "lang": { "en-us": { "role": { "documentation": "Private Placement Abstract", "label": "Private Placement [Abstract]" } } }, "auth_ref": [] }, "pkbo_PrivatePlacementDescription": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PrivatePlacementDescription", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private placement, description", "label": "PrivatePlacementDescription", "documentation": "Private placement, description." } } }, "auth_ref": [] }, "pkbo_PrivatePlacementDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PrivatePlacementDetailsLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails" ], "lang": { "en-us": { "role": { "documentation": "Private Placement Details Line Items", "label": "Private Placement (Details) [Line Items]" } } }, "auth_ref": [] }, "pkbo_PrivatePlacementDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PrivatePlacementDetailsTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails" ], "lang": { "en-us": { "role": { "documentation": "Private Placement Details Table", "label": "Private Placement (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables", "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement [Member]", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "pkbo_PrivatePlacementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PrivatePlacementTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacement" ], "lang": { "en-us": { "role": { "documentation": "Private Placement Text Block", "terseLabel": "Private Placement", "label": "PrivatePlacementTextBlock" } } }, "auth_ref": [] }, "pkbo_PrivatePlacementWarrantsLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PrivatePlacementWarrantsLiabilityMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement Warrants Liability [Member]", "label": "Private Placement Warrants Liability [Member]", "documentation": "Private Placement Warrants Liability." } } }, "auth_ref": [] }, "pkbo_PrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PrivatePlacementWarrantsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficitParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement Warrants [Member]", "documentation": "Private placement warrants.", "verboseLabel": "Private Placement Warrants [Member]", "label": "PrivatePlacementWarrantsMember" } } }, "auth_ref": [] }, "pkbo_ProceedsFromCompletionOfBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ProceedsFromCompletionOfBusinessCombination", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashFlowsRelatedBusinessCombinationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from completion of business combination.", "label": "Proceeds from Completion of Business Combination", "terseLabel": "Proceeds from completion of business combination", "verboseLabel": "Net cash and restricted cash transactions", "totalLabel": "Total" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromContributedCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromContributedCapital", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital contribution from related party", "label": "Proceeds from Contributed Capital", "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromContributionsFromAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromContributionsFromAffiliates", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Contributions from Affiliates", "terseLabel": "Proceeds from net shareholder contributions", "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from issuance of Convertible Notes, net of debt issuance costs", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuance of convertible promissory notes", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r46" ] }, "pkbo_ProceedsFromInsuranceFinancingNote": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ProceedsFromInsuranceFinancingNote", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from Insurance Financing Note", "label": "Proceeds from Insurance Financing Note", "documentation": "Proceeds from insurance financing note." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross proceeds from Initial public offering", "terseLabel": "Proceeds from Initial Public Offering, net of underwriters' fees", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common shares", "verboseLabel": "Aggregate gross proceeds", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "terseLabel": "proceeds from loan", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r947" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "verboseLabel": "Less: cash proceeds from PIPE subscribers", "terseLabel": "Less: proceeds from issuance of shares to PIPE subscribers", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSecuredDebt", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of secured note", "label": "Proceeds from Issuance of Secured Debt", "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Proceeds from warrant", "label": "Proceeds from Issuance or Sale of Equity", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r6", "r650" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of promissory note to related party", "label": "Proceeds from Related Party Debt", "verboseLabel": "Proceeds from related party loan", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from (repayment of) related party loans", "label": "Proceeds from (Repayments of) Related Party Debt", "verboseLabel": "Repayment of related party loan", "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfSecuredDebt", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from issuance of secured note", "terseLabel": "Proceeds from a Senior Secured Promissory Note", "label": "Proceeds from (Repayments of) Secured Debt", "documentation": "Amount of cash inflow (outflow) from long-term debt wholly or partially secured by collateral. Excludes tax exempt secured debt." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of warrants", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r24" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r279", "r592", "r627", "r628", "r629", "r630", "r631", "r632", "r784", "r805", "r824", "r928", "r981", "r982", "r989", "r1051" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r279", "r592", "r627", "r628", "r629", "r630", "r631", "r632", "r784", "r805", "r824", "r928", "r981", "r982", "r989", "r1051" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "verboseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r182", "r201", "r203", "r214", "r222", "r234", "r244", "r245", "r260", "r272", "r276", "r278", "r317", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r502", "r505", "r506", "r520", "r525", "r608", "r621", "r659", "r711", "r733", "r734", "r794", "r820", "r821", "r835", "r946", "r984" ] }, "pkbo_PromissoryNoteAssumed": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PromissoryNoteAssumed", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Promissory note assumed.", "label": "Promissory Note Assumed", "terseLabel": "Promissory note assumed" } } }, "auth_ref": [] }, "pkbo_PromissoryNoteCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PromissoryNoteCurrent", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Promissory note", "label": "Promissory Note Current", "documentation": "Promissory Note Current" } } }, "auth_ref": [] }, "pkbo_PromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PromissoryNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Promissory Notes [Member]", "documentation": "Promissory notes." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r131", "r168", "r171", "r172" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Gross property and equipment", "terseLabel": "Gross property and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r132", "r186", "r619" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Net property and equipment", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r11", "r609", "r619", "r823" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r11", "r168", "r171", "r617" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property Plant and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r132" ] }, "pkbo_PublicOfferingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PublicOfferingAbstract", "lang": { "en-us": { "role": { "documentation": "Public Offering Abstract", "label": "Public Offering [Abstract]" } } }, "auth_ref": [] }, "pkbo_PublicOfferingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PublicOfferingTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOffering" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Public Offering", "label": "PublicOfferingTextBlock", "documentation": "The entire disclosure of public offering." } } }, "auth_ref": [] }, "pkbo_PublicWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PublicWarrantsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Public warrants.", "label": "Public Warrants [Member]", "terseLabel": "Public Warrants [Member]" } } }, "auth_ref": [] }, "pkbo_PurchaseOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PurchaseOfShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of shares (in Shares)", "label": "Purchase Of Shares", "documentation": "Purchase of shares." } } }, "auth_ref": [] }, "pkbo_PurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PurchasePricePerShare", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase price per share.", "label": "Purchase Price Per Share", "terseLabel": "Purchase price, per share" } } }, "auth_ref": [] }, "pkbo_PurchasePricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "PurchasePricePercentage", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase price percentage.", "label": "Purchase Price Percentage", "terseLabel": "Purchase price percentage" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r878" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r878" ] }, "pkbo_QuantitativeInformationRegardingCompanysLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "QuantitativeInformationRegardingCompanysLeasesTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Quantitative information regarding company\u2019s leases.", "label": "Quantitative Information Regarding Company's Leases [Table Text Block]", "verboseLabel": "Summary of Quantitative Information Regarding Company's Leases" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r338", "r339", "r340", "r341", "r413", "r421", "r453", "r454", "r455", "r567", "r591", "r636", "r681", "r682", "r743", "r746", "r748", "r749", "r759", "r781", "r782", "r796", "r804", "r817", "r825", "r828", "r977", "r988", "r1041", "r1042", "r1043", "r1044", "r1045" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r338", "r339", "r340", "r341", "r413", "r421", "r453", "r454", "r455", "r567", "r591", "r636", "r681", "r682", "r743", "r746", "r748", "r749", "r759", "r781", "r782", "r796", "r804", "r817", "r825", "r828", "r977", "r988", "r1041", "r1042", "r1043", "r1044", "r1045" ] }, "pkbo_RecapitalizationMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RecapitalizationMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashFlowsRelatedBusinessCombinationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Recapitalization", "label": "Recapitalization [Member]", "documentation": "Recapitalization" } } }, "auth_ref": [] }, "pkbo_ReclassificationOfConvertibleNoteWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ReclassificationOfConvertibleNoteWarrants", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification of April 2023 Convertible Note Warrants from Liability to Equity", "label": "Reclassification of Convertible Note Warrants", "documentation": "Reclassification of convertible note warrants." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r844", "r856", "r866", "r892" ] }, "pkbo_RedemptionOfIgnyteShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RedemptionOfIgnyteShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNumberOfSharesOfCommonStockIssuedImmediatelyFollowingTheConsummationOfTheBusine" ], "lang": { "en-us": { "role": { "terseLabel": "Less: redemption of Ignyte shares", "label": "Redemption Of Ignyte Shares", "documentation": "Redemption of ignyte shares." } } }, "auth_ref": [] }, "pkbo_ReimbursementOfCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ReimbursementOfCostsAndExpenses", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Reimbursement of costs and expenses.", "label": "Reimbursement Of Costs And Expenses", "terseLabel": "Reimbursement of costs and expenses" } } }, "auth_ref": [] }, "pkbo_RelatedPartyCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RelatedPartyCosts1", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Costs", "label": "Related Party Costs 1", "documentation": "Related party costs 1." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r420", "r552", "r553", "r684", "r685", "r686", "r687", "r688", "r708", "r710", "r742" ] }, "pkbo_RelatedPartyLoanForSettlementOfAccruedLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RelatedPartyLoanForSettlementOfAccruedLiability", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Related party loan for settlement of accrued liability", "label": "Related Party Loan for Settlement of Accrued Liability", "terseLabel": "Related party loan entered into for settlement of accrued expenses" } } }, "auth_ref": [] }, "pkbo_RelatedPartyLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RelatedPartyLoans", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Related party loans.", "label": "Related Party Loans", "terseLabel": "Related party loans" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Member]", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r225", "r226", "r552", "r553", "r554", "r555", "r684", "r685", "r686", "r687", "r688", "r708", "r710", "r742" ] }, "pkbo_RelatedPartyTransactionAccountsPayableAndGeneralFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RelatedPartyTransactionAccountsPayableAndGeneralFinancingActivities", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails" ], "lang": { "en-us": { "role": { "documentation": "Related party transaction accounts payable and general financing activities.", "label": "Related Party Transaction Accounts Payable and General Financing Activities", "terseLabel": "Accounts payable and general financing activities" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r552", "r553", "r1037" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "pkbo_RelatedPartyTransactionLeasePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RelatedPartyTransactionLeasePayment", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Related party transaction lease payment.", "label": "Related Party Transaction Lease Payment", "terseLabel": "Lease payment" } } }, "auth_ref": [] }, "pkbo_RelatedPartyTransactionNetIncreaseInContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RelatedPartyTransactionNetIncreaseInContributions", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails" ], "lang": { "en-us": { "role": { "documentation": "Related party transaction net increase in contributions.", "label": "Related Party Transaction Net Increase In Contributions", "totalLabel": "Net increase in contributions from member" } } }, "auth_ref": [] }, "pkbo_RelatedPartyTransactionResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RelatedPartyTransactionResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails" ], "lang": { "en-us": { "role": { "documentation": "Related party transaction research and development.", "label": "Related Party Transaction Research and Development", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r420", "r552", "r553", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r684", "r685", "r686", "r687", "r688", "r708", "r710", "r742", "r1037" ] }, "pkbo_RelatedPartyTransactionsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RelatedPartyTransactionsDetailsLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Related Party Transactions Details Line Items", "label": "Related Party Transactions (Details) [Line Items]" } } }, "auth_ref": [] }, "pkbo_RelatedPartyTransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RelatedPartyTransactionsDetailsTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Related Party Transactions Details Table", "label": "Related Party Transactions (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCosts1" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "Related Party Transactions and Shared Service Costs", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r549", "r550", "r551", "r553", "r556", "r656", "r657", "r658", "r717", "r718", "r719", "r739", "r741" ] }, "pkbo_RepaymentOfInsuranceFinancingNote": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RepaymentOfInsuranceFinancingNote", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of Insurance Financing Note", "negatedTerseLabel": "Repayment of Insurance Financing Note", "label": "Repayment of Insurance Financing Note", "documentation": "Repayment of insurance financing note." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Repayments of Debt", "terseLabel": "Repayment of debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r948" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Payment of Convertible Notes", "negatedTerseLabel": "Repayment of Promissory Note", "terseLabel": "Repayment of Promissory Note", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r47" ] }, "pkbo_RepaymentsOfUpfrontPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RepaymentsOfUpfrontPayments", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Repayments of upfront payments.", "label": "Repayments Of Upfront Payments", "terseLabel": "Repayments of upfront payments" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r227", "r228", "r356", "r384", "r555", "r789", "r790" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r100", "r471", "r1046" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r470" ] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAdjustmentMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "auth_ref": [ "r231", "r232", "r233", "r242", "r243", "r256", "r518", "r519", "r922", "r923", "r924", "r925", "r926", "r931", "r932" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r181", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r256", "r319", "r320", "r490", "r517", "r518", "r519", "r520", "r536", "r547", "r548", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r845", "r857", "r867", "r893" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r846", "r858", "r868", "r894" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r853", "r865", "r875", "r901" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r181", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r256", "r319", "r320", "r490", "r517", "r518", "r519", "r520", "r536", "r547", "r548", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647" ] }, "pkbo_RestrictedBankAccountCollateralForCreditCard": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RestrictedBankAccountCollateralForCreditCard", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Restricted Bank Account Collateral For Credit Card", "label": "Restricted Bank Account Collateral For Credit Card", "terseLabel": "Restricted bank account collateral for credit card" } } }, "auth_ref": [] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Restricted Cash, Total", "label": "Restricted Cash", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r941", "r951", "r1047", "r1050" ] }, "pkbo_RestrictedCashCollateralForSecuredLetterOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RestrictedCashCollateralForSecuredLetterOfCredit", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Restricted cash collateral for secured letter of credit.", "label": "Restricted Cash Collateral for Secured Letter of Credit", "terseLabel": "Restricted cash collateral for secured letter of credit" } } }, "auth_ref": [] }, "pkbo_RestrictedCashForwardSharePurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RestrictedCashForwardSharePurchaseAgreement", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashFlowsRelatedBusinessCombinationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Plus: restricted cash - Forward Share Purchase Agreement", "label": "Restricted Cash Forward Share Purchase Agreement", "documentation": "Restricted cash forward share purchase agreement" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r162", "r942", "r951" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r110", "r140", "r615", "r641", "r646", "r654", "r692", "r823" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r180", "r231", "r232", "r233", "r235", "r243", "r245", "r318", "r321", "r462", "r463", "r464", "r489", "r490", "r509", "r511", "r512", "r514", "r518", "r637", "r639", "r660", "r1058" ] }, "pkbo_ReturnFromRepaymentOfUpfrontPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ReturnFromRepaymentOfUpfrontPayments", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "documentation": "Return from repayment of upfront payments.", "label": "Return From Repayment Of Upfront Payments", "terseLabel": "Return from repayment of upfront payments" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreementsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r261", "r262", "r271", "r274", "r275", "r279", "r280", "r282", "r409", "r410", "r592" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenue" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Grant Revenue", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r176", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r412" ] }, "pkbo_RevenueFromGrantsRemainingFundingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "RevenueFromGrantsRemainingFundingCapacity", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue from grants remaining funding capacity.", "label": "Revenue From Grants Remaining Funding Capacity", "terseLabel": "Available remaining fund" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Grant Revenue", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r713", "r783", "r791" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Revenues, Total", "label": "Revenues", "terseLabel": "Grant revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r210", "r222", "r261", "r262", "r271", "r274", "r275", "r279", "r280", "r282", "r317", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r525", "r608", "r984" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfQuantitativeInformationRegardingCompanysLeasesDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "verboseLabel": "Operating lease liabilities arising from obtaining right of use assets", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r543", "r822" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r910" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r910" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of warrants", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables", "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails", "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails", "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficitParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of PIPE Shares, shares", "terseLabel": "Number of sale of units", "label": "Issuance of shares to PIPE Subscribers, shares", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "pkbo_SaleOfStockNumberOfWarrantsIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SaleOfStockNumberOfWarrantsIssuedInTransaction", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of private placement warrants", "label": "SaleOfStockNumberOfWarrantsIssuedInTransaction", "documentation": "Sale of private placement warrants." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Sale ofstock price", "verboseLabel": "Initial public offering per share", "terseLabel": "Share price per units (in Dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario Forecast [Member]", "label": "Forecast [Member]" } } }, "auth_ref": [ "r422", "r962" ] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioPreviouslyReportedMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "auth_ref": [ "r181", "r231", "r233", "r234", "r235", "r236", "r237", "r245", "r256", "r490", "r517", "r518", "r519", "r536", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r926", "r929", "r930", "r931", "r961", "r973", "r974", "r1026", "r1032", "r1033" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r246", "r422", "r920", "r962" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Dilutive Securities Excluded from Calculation of Net Loss Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r501" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r145" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of Components of Deferred Tax Assets (Liabilities)", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r144" ] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Income (Loss) Per Common Share", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share." } } }, "auth_ref": [ "r55", "r58", "r963" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of Reconciliation of the Federal Income Tax Effective Rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r143" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationScheduleOfSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Share-Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r73" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r314", "r315", "r316" ] }, "pkbo_ScheduleOfNetIncomePerCommonShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ScheduleOfNetIncomePerCommonShareAbstract", "lang": { "en-us": { "role": { "documentation": "Schedule Of Net Income Per Common Share Abstract", "label": "Schedule of Net Income Per Common Share [Abstract]" } } }, "auth_ref": [] }, "pkbo_ScheduleOfNumberOfSharesOfCommonStockIssuedImmediatelyFollowingTheConsummationOfTheBusinessCombinationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ScheduleOfNumberOfSharesOfCommonStockIssuedImmediatelyFollowingTheConsummationOfTheBusinessCombinationTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Number Of Shares of Common Stock Issued Immediately Following the Consummation of the Business Combination", "label": "Schedule Of Number Of Shares Of Common Stock Issued Immediately Following The Consummation Of The Business Combination [Table Text Block]", "documentation": "Tabular disclosure of number of shares of common stock issued immediately following the consummation of the business combination." } } }, "auth_ref": [] }, "pkbo_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextblock": { "xbrltype": "textBlockItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextblock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Prepaid And Other Current Assets", "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table TextBlock]", "documentation": "Tabular disclosure of prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureAssetsSummaryOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r147" ] }, "pkbo_ScheduleOfReconciliationOfCashFlowsRelatingBusinessCombinationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ScheduleOfReconciliationOfCashFlowsRelatingBusinessCombinationTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Cash Flows Related Business Combination", "label": "Schedule Of Reconciliation Of Cash Flows Relating Business Combination [Table Text Block]", "documentation": "Tabular disclosure of reconciliation of cash flows relating business combination." } } }, "auth_ref": [] }, "pkbo_ScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatingBusinessCombinationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatingBusinessCombinationTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Changes in Stockholders' Deficit Related Business Combination", "label": "Schedule Of Reconciliation Of Changes In Stockholders' Equity (Deficit) Relating Business Combination[Table Text Block]", "documentation": "Tabular disclosure of reconciliation of changes in stockholders' equity (deficit) relating business combination." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r94", "r95", "r715", "r716", "r719" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsTables", "http://peak-bio.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of Components of net Transfers from pH Pharma", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtTables", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r424", "r426", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r452", "r453", "r454", "r455", "r456" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of stock option activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r20", "r21", "r72" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Assumptions Used in Determining Fair Value of Stock Options", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Fair Value of Share-based Awards Measured with Weighted-Average Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r142" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Summary of Company's Outstanding Warrants", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r70" ] }, "pkbo_SecuredLetterOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SecuredLetterOfCredit", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Secured letter of credit.", "label": "Secured Letter of Credit", "terseLabel": "Secured letter of credit" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r840" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r839" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r280", "r281", "r674", "r676", "r678", "r745", "r747", "r751", "r761", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r785", "r806", "r828", "r989", "r1051" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r270", "r280", "r795" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "totalLabel": "Selling, General and Administrative Expense, Total", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r120" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "General and Administrative Costs", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r12" ] }, "pkbo_SeniorSecuredPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SeniorSecuredPromissoryNoteMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Secured Promissory Note [Member]", "label": "Senior Secured Promissory Note [Member]", "documentation": "Senior Secured Promissory Note Member" } } }, "auth_ref": [] }, "pkbo_SettlementOfForwardPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SettlementOfForwardPurchaseAgreement", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Settlement of forward purchase agreement.", "label": "Settlement Of Forward Purchase Agreement", "terseLabel": "Settlement of forward purchase agreement" } } }, "auth_ref": [] }, "pkbo_SettlementOfForwardPurchaseAgreementShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SettlementOfForwardPurchaseAgreementShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Settlement of Forward Purchase Agreement, shares", "terseLabel": "Settlement of Forward Purchase Agreement, shares", "documentation": "Settlement of forward purchase agreement in shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "pkbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscount": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscount", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discounted", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount", "documentation": "Share based compensation arrangement by share based payment award fair value assumptions discount." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Dollars per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price", "verboseLabel": "Stock price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueOfSharebasedAwardsMeasuredWithWeightedaverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r454" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueOfSharebasedAwardsMeasuredWithWeightedaverageAssumptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r453" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueOfSharebasedAwardsMeasuredWithWeightedaverageAssumptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r455" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtTables", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r424", "r426", "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r452", "r453", "r454", "r455", "r456" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "pkbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAllocatedInSpinOff": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAllocatedInSpinOff", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options allocated in spin off.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Allocated in Spin off", "terseLabel": "shares, allocation of stock options in spin-off" } } }, "auth_ref": [] }, "pkbo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedInSpinOff": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExchangedInSpinOff", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares, exchanged of stock options in spin-off", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Exchanged in Spin Off", "documentation": "Share based compensation arrangement by share based payment award options exchanged in spin off." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Shares, Exercisable", "terseLabel": "Shares, Exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r434" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price of warrants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r434" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "terseLabel": "Shares, Cancelled/Forfeited", "negatedLabel": "Shares, Cancelled/Forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r438" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Shares, Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r436" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodStartLabel": "Aggregate Intrinsic Value, Outstanding Beginning Balance", "periodEndLabel": "Aggregate Intrinsic Value, Outstanding Ending Balance", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Outstanding options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "terseLabel": "Stock options", "periodStartLabel": "Shares, Outstanding Beginning Balance", "periodEndLabel": "Shares, Outstanding Ending Balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r432", "r433" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning Balance", "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending Balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r432", "r433" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r428", "r429", "r430", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r452", "r453", "r454", "r455", "r456" ] }, "pkbo_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAllocatedInSpinOffWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAllocatedInSpinOffWeightedAverageExercisePrice", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share Based payment award options allocated in spin off weighted average exercise price.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Allocated in Spin off Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price,Allocation of stock options in spin-off" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r437" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Cancelled / Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r438" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r436" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Tranches A [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Tranches B [Member]", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r423", "r431", "r450", "r451", "r452", "r453", "r456", "r465", "r466", "r467", "r468" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails", "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Initial public offering per share (in Dollars per share)", "terseLabel": "Share price (in Dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Grants vest percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r991" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Term of stock option", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r819" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityScheduleOfWeightedAverageAssumptionsUsedInDeterminingFairValueOfStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfFairValueOfSharebasedAwardsMeasuredWithWeightedaverageAssumptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r452" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r71" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r71" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r141" ] }, "pkbo_SharesAcquiredInReverseRecapitalizationNetOfTransactionFees": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SharesAcquiredInReverseRecapitalizationNetOfTransactionFees", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Shares acquired in reverse recapitalization net of transaction fees.", "label": "Shares Acquired In Reverse Recapitalization Net Of Transaction Fees", "terseLabel": "Shares acquired in reverse recapitalization net of transaction fees" } } }, "auth_ref": [] }, "pkbo_SharesAcquiredInReverseRecapitalizationNetOfTransactionFeesShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SharesAcquiredInReverseRecapitalizationNetOfTransactionFeesShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Shares acquired in reverse recapitalization net of transaction fees shares.", "label": "Shares Acquired In Reverse Recapitalization Net Of Transaction Fees Shares", "terseLabel": "Shares acquired in reverse recapitalization net of transaction fees, shares" } } }, "auth_ref": [] }, "pkbo_SharesIssuedForSettlementOfConvertibleNotesPayableAndAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SharesIssuedForSettlementOfConvertibleNotesPayableAndAccruedInterest", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Shares issued for settlement of convertible notes payable and accrued interest.", "label": "Shares Issued for Settlement of Convertible Notes Payable and Accrued Interest", "terseLabel": "Shares issued for settlement of convertible notes payable and accrued interest" } } }, "auth_ref": [] }, "pkbo_SharesIssuedForSettlementOfRelatedPartyLoanAndAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SharesIssuedForSettlementOfRelatedPartyLoanAndAccruedInterest", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Shares issued for settlement of related party loan and accrued interest.", "label": "Shares Issued for Settlement of Related Party Loan and Accrued Interest", "terseLabel": "Shares issued for settlement of related party loan and accrued interest" } } }, "auth_ref": [] }, "pkbo_SharesIssuedOrServicesAndDebtSettlement": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SharesIssuedOrServicesAndDebtSettlement", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNumberOfSharesOfCommonStockIssuedImmediatelyFollowingTheConsummationOfTheBusine" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued for services and debt settlement", "label": "Shares Issued Or Services And Debt Settlement", "documentation": "Shares issued for services and debt settlement." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Representative Shares issued price per share (in Dollars per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Outstanding", "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Short-Term Debt, Total", "label": "Short-Term Debt", "terseLabel": "Short term borrowings", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r102", "r152", "r823", "r1048" ] }, "pkbo_ShortTermDebtInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ShortTermDebtInterestRate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Short term debt interest rate.", "label": "Short Term Debt Interest Rate", "terseLabel": "Short term debt interest rate" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "pkbo_ShortTermDebtTerm": { "xbrltype": "durationItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ShortTermDebtTerm", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Short term debt term.", "label": "Short Term Debt Term", "terseLabel": "Short term debt term" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtTables", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueStockOptionsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtTables", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r29" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r128", "r219" ] }, "pkbo_SponsorMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SponsorMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Sponsor Member", "label": "Sponsor [Member]" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "terseLabel": "State", "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r178", "r191", "r192", "r193", "r222", "r249", "r250", "r252", "r254", "r258", "r259", "r317", "r343", "r345", "r346", "r347", "r350", "r351", "r382", "r383", "r386", "r389", "r396", "r525", "r650", "r651", "r652", "r653", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r691", "r712", "r735", "r762", "r763", "r764", "r765", "r766", "r919", "r952", "r964" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficitParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r16", "r41", "r180", "r206", "r207", "r208", "r231", "r232", "r233", "r235", "r243", "r245", "r257", "r318", "r321", "r398", "r462", "r463", "r464", "r489", "r490", "r509", "r510", "r511", "r512", "r513", "r514", "r518", "r527", "r528", "r529", "r530", "r531", "r532", "r548", "r637", "r638", "r639", "r660", "r735" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r280", "r281", "r674", "r676", "r678", "r745", "r747", "r751", "r761", "r768", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r785", "r806", "r828", "r989", "r1051" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficitParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r231", "r232", "r233", "r257", "r592", "r648", "r671", "r683", "r684", "r685", "r686", "r687", "r688", "r691", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r704", "r705", "r706", "r707", "r708", "r710", "r713", "r714", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r735", "r829" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r246", "r422", "r920", "r921", "r962" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficitParentheticals", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r231", "r232", "r233", "r257", "r592", "r648", "r671", "r683", "r684", "r685", "r686", "r687", "r688", "r691", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r704", "r705", "r706", "r707", "r708", "r710", "r713", "r714", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r735", "r829" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r848", "r860", "r870", "r896" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Share based Payment Arrangement", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r965" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination with Ignyte, net of transaction costs (Note 1), shares", "label": "Stock Issued During Period, Shares, Acquisitions", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r107", "r108", "r140" ] }, "pkbo_StockIssuedDuringPeriodSharesAdditionalCommitmentShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "StockIssuedDuringPeriodSharesAdditionalCommitmentShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares additional commitment shares.", "label": "Stock Issued During Period Shares Additional Commitment Shares", "terseLabel": "Additional commitment shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in settlement of 2022 Pre-Business Combination Convertible Notes and the Director Loan, shares", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r16", "r40", "r68", "r140", "r369" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, shares", "verboseLabel": "Number of shares issue (in Shares)", "label": "Issuance of common stock, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r16", "r107", "r108", "r140", "r650", "r735", "r763" ] }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under White Lion Purchase Agreement, shares", "label": "Stock Issued During Period, Shares, Purchase of Assets", "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r16", "r107", "r108", "r140", "r437" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination with Ignyte, net of transaction costs (Note 1)", "totalLabel": "Total", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r16", "r41", "r140" ] }, "pkbo_StockIssuedDuringPeriodValueAdditionalCommitmentShares": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "StockIssuedDuringPeriodValueAdditionalCommitmentShares", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value additional commitment shares", "label": "Stock Issued During Period Value Additional Commitment Shares", "terseLabel": "Additional commitment Value" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock in settlement of 2022 Pre-Business Combination Convertible Notes and the Director Loan", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r16", "r41", "r140" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "verboseLabel": "Purchase price of founder shares", "label": "Issuance of common stock", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r16", "r107", "r108", "r140", "r660", "r735", "r763", "r835" ] }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under White Lion Purchase Agreement", "label": "Stock Issued During Period, Value, Purchase of Assets", "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase and retirement of share under Forward Share Purchase Agreement, Shares", "verboseLabel": "Repurchase and retirement of share under Forward Share Purchase Agreement", "label": "Stock Repurchased and Retired During Period, Shares", "terseLabel": "Less: retirement of shares issued pursuant to forward purchase agreement", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r16", "r107", "r108", "r140" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase and retirement of share under Forward Share Purchase Agreement", "label": "Stock Repurchased and Retired During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r16", "r107", "r108", "r140" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "verboseLabel": "Stock repurchased during period, shares", "terseLabel": "Common stock, Share", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r16", "r107", "r108", "r140", "r653", "r735", "r765" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets", "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' deficit", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "terseLabel": "Total deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r108", "r111", "r112", "r130", "r693", "r709", "r736", "r737", "r823", "r836", "r954", "r972", "r1028", "r1058" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Deficit", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "pkbo_StockholdersEquityDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "StockholdersEquityDetailsLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Stockholders Equity Details Line Items", "label": "Stockholders' Equity (Details) [Line Items]" } } }, "auth_ref": [] }, "pkbo_StockholdersEquityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "StockholdersEquityDetailsTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Stockholders Equity Details Table", "label": "Stockholders' Equity (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r137", "r221", "r381", "r383", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r395", "r398", "r516", "r738", "r740", "r767" ] }, "pkbo_SubscriptionAgreementToExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SubscriptionAgreementToExchange", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subscription agreement to exchange", "label": "Subscription Agreement To Exchange", "documentation": "Subscription agreement to exchange." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r533", "r559" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r533", "r559" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r533", "r559" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "pkbo_SubsequentEventsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SubsequentEventsDetailsLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Subsequent Events Details Line Items", "label": "Subsequent Events (Details) [Line Items]" } } }, "auth_ref": [] }, "pkbo_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SubsequentEventsDetailsTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Subsequent Events Details Table", "label": "Subsequent Events (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r558", "r560" ] }, "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest", "terseLabel": "Ownership percentage in subsidiary", "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership." } } }, "auth_ref": [] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables", "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails", "http://peak-bio.com/20231231/taxonomy/role/PrivatePlacementDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "pkbo_SummaryofSignificantAccountingPoliciesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashFlowsRelatedBusinessCombinationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail" ], "lang": { "en-us": { "role": { "documentation": "Summaryof Significant Accounting Policies Details Line Items", "label": "Summary of Significant Accounting Policies (Details) [Line Items]" } } }, "auth_ref": [] }, "pkbo_SummaryofSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfNetTransfersFromPhPharmaDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashFlowsRelatedBusinessCombinationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfChangesInStockholdersEquityDeficitRelatedBusinessCombinationDetail" ], "lang": { "en-us": { "role": { "documentation": "Summaryof Significant Accounting Policies Details Table", "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of non-cash financing activities:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r889" ] }, "pkbo_TemporaryStockRetroactiveApplicationOfRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "TemporaryStockRetroactiveApplicationOfRecapitalization", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Temporary Stock Retroactive Application Of Recapitalization", "label": "Temporary Stock Retroactive Application Of Recapitalization", "terseLabel": "Retroactive application of recapitalization" } } }, "auth_ref": [] }, "pkbo_TemporaryStockRetroactiveApplicationOfRecapitalizationShares": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "TemporaryStockRetroactiveApplicationOfRecapitalizationShares", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Temporary Stock Retroactive Application Of Recapitalization, shares", "label": "Temporary Stock Retroactive Application Of Recapitalization, shares", "terseLabel": "Retroactive application of recapitalization, shares" } } }, "auth_ref": [] }, "pkbo_ThroughIPOAndOverAllotmentMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "ThroughIPOAndOverAllotmentMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfEquityDeficitParentheticals" ], "lang": { "en-us": { "role": { "documentation": "Through I P O And Over Allotment Member", "terseLabel": "Through IPO and over-allotment [Member]", "label": "ThroughIPOAndOverAllotmentMember" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r967", "r1036" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "pkbo_TotalIgnyteShares1": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "TotalIgnyteShares1", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfNumberOfSharesOfCommonStockIssuedImmediatelyFollowingTheConsummationOfTheBusine" ], "lang": { "en-us": { "role": { "terseLabel": "Total Ignyte shares", "label": "Total Ignyte Shares 1", "documentation": "Total Ignyte shares." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r881" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r888" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r909" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r911" ] }, "us-gaap_TransferAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferAgentMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "May 2024 Placement Agent [Member]", "label": "Transfer Agent [Member]", "documentation": "Financial institution maintaining investor record, account balance and company's stock transaction." } } }, "auth_ref": [ "r990" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r377", "r394", "r515", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r623", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r968", "r969", "r970", "r971" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r912" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r913" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r911" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r911" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r914" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r912" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total purchase price", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r16", "r69", "r140" ] }, "pkbo_TwoThousandTwentyOneFounderLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "TwoThousandTwentyOneFounderLoanMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "2021 Founder Loans [Member]", "label": "Two Thousand Twenty One Founder Loan [Member]", "documentation": "2021 Founder Loans." } } }, "auth_ref": [] }, "pkbo_TwoThousandTwentyTwoLongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "TwoThousandTwentyTwoLongTermIncentivePlanMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSharebasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2022 Long Term Incentive Plan [Member]", "label": "Two Thousand Twenty Two Long Term Incentive Plan [Member]", "documentation": "Two thousand twenty two long term incentive plan." } } }, "auth_ref": [] }, "pkbo_TwoThousandTwentyTwoPreBusinessCombinationMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "TwoThousandTwentyTwoPreBusinessCombinationMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Two Thousand Twenty Two Pre-Business Combination [Member]", "label": "Two Thousand Twenty Two Pre-Business Combination [Member]", "documentation": "Two thousand twenty two pre-business combination." } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreementsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r501" ] }, "us-gaap_TypeOfRevenueExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRevenueExtensibleList", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenue, Product and Service [Extensible Enumeration]", "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [] }, "pkbo_UnderwriterAndOrItsDesigneesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "UnderwriterAndOrItsDesigneesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Underwriter And Or Its Designees Member", "terseLabel": "Underwriter (and/or its designees) [Member]", "label": "Underwriter And Or Its Designees [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r908" ] }, "pkbo_UnpaidCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "UnpaidCompensation", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid compensation", "label": "Unpaid Compensation", "documentation": "Unpaid compensation." } } }, "auth_ref": [] }, "pkbo_UnsecuredConvertiblePromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "UnsecuredConvertiblePromissoryNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured Convertible Promissory Notes [Member]", "label": "Unsecured Convertible Promissory Notes [Member]", "documentation": "Unsecured convertible promissory notes." } } }, "auth_ref": [] }, "pkbo_UnsecuredCovertiblePromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "UnsecuredCovertiblePromissoryNotesMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Unsecured Covertible Promissory Notes[Member]", "label": "Unsecured Covertible Promissory Notes[Member]", "terseLabel": "Unsecured Convertible Promissory Notes" } } }, "auth_ref": [] }, "pkbo_Upfrontpaymentreceived": { "xbrltype": "monetaryItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "Upfrontpaymentreceived", "crdr": "debit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Upfront payment received.", "label": "UpfrontPaymentReceived", "terseLabel": "Upfront payment from collaboration agreement" } } }, "auth_ref": [] }, "pkbo_UsArmyMedicaResearchAcquisitionActivityMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "UsArmyMedicaResearchAcquisitionActivityMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureGrantRevenueAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "US army medica research acquisition activity.", "label": "US Army Medica Research Acquisition Activity [Member]" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r59", "r60", "r61", "r164", "r166", "r169", "r170" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Net decrease of valuation allowance", "terseLabel": "Change in Valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r481" ] }, "pkbo_VennLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "VennLicenseAgreementMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureAccruedExpensesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureCollaborativeAndLicensingAgreementsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Venn license agreement.", "label": "Venn License Agreement [Member]", "terseLabel": "Venn License Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016" ] }, "pkbo_WarrantCoverageOnCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "WarrantCoverageOnCommonStock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "documentation": "Warrant coverage on common stock.", "label": "Warrant Coverage On Common Stock", "terseLabel": "Warrant coverage on common stock" } } }, "auth_ref": [] }, "pkbo_WarrantCoverageOnCommonStockPriorToTheConsummationOfTheBusinessCombination": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "WarrantCoverageOnCommonStockPriorToTheConsummationOfTheBusinessCombination", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details" ], "lang": { "en-us": { "role": { "documentation": "Warrant coverage on common stock prior to the consummation of the business combination.", "label": "Warrant Coverage on Common Stock Prior To The Consummation of The Business Combination", "terseLabel": "Warrant coverage on common stock prior to the consummation of the business combination" } } }, "auth_ref": [] }, "pkbo_WarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "WarrantLiabilityMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrant Liability Member", "terseLabel": "Warrant Liability [Member]", "label": "WarrantLiabilityMember" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/CoverPage", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromCalculationOfNetLossPerShareDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Warrants [Member]", "label": "Warrant [Member]", "verboseLabel": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r826", "r827", "r830", "r831", "r832", "r833" ] }, "pkbo_WarrantRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "WarrantRedemptionPricePerShare", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/InitialPublicOfferingDetails", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant redemption price per share", "label": "WarrantRedemptionPricePerShare", "documentation": "Warrant redemption price per share." } } }, "auth_ref": [] }, "pkbo_WarrantSubscriptionAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "WarrantSubscriptionAgreementsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant Subscription Agreements [Member]", "documentation": "Warrant Subscription Agreements[Member]", "label": "Warrant Subscription Agreements[Member]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants outstanding", "terseLabel": "PIPE warrants outstanding", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDescriptionOfTheBusinessDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrant expiration date", "terseLabel": "Expiration Date", "label": "Warrants and Rights Outstanding, Maturity Date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r1027" ] }, "pkbo_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "WarrantsMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAndSharedServiceCostsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants Member", "terseLabel": "Warrants [Member]", "label": "WarrantsMember" } } }, "auth_ref": [] }, "pkbo_WarrantsToPurchaseCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "WarrantsToPurchaseCommonStock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails", "http://peak-bio.com/20231231/taxonomy/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants To Purchase Common Stock", "label": "Warrants To Purchase Common Stock", "terseLabel": "Warrant To Purchase Shares of Common Stock" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and diluted weighted average shares outstanding, common stock (in Shares)", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted average number of shares outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r248", "r254" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "terseLabel": "Weighted average number of shares outstanding, basic (in Shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r247", "r254" ] }, "pkbo_WeightedAveragePriceOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "WeightedAveragePriceOfCommonStock", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureDebtAdditionalInformation1Details", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of common stock.", "label": "Weighted Average price of Common Stock", "terseLabel": "Weighted average price of common stock" } } }, "auth_ref": [] }, "pkbo_WhiteLionDerivativeLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "WhiteLionDerivativeLiabilityMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInLevel3LiabilitiesAssetsMeasuredAtFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "White Lion Derivative Liability [Member]", "label": "White Lion Derivative Liability [Member]", "documentation": "White Lion Derivative Liability." } } }, "auth_ref": [] }, "pkbo_WhiteLionPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://peak-bio.com/20231231", "localname": "WhiteLionPurchaseAgreementMember", "presentation": [ "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWeightedAverageAssumptionsUsedInDeterminingTheFairValueDetails", "http://peak-bio.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables", "http://peak-bio.com/20231231/taxonomy/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "documentation": "White lion purchase agreement member.", "label": "White Lion Purchase Agreement [Member]", "terseLabel": "White Lion Purchase Agreement [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481648/480-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)(2)", "SubTopic": "40", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-6" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.14)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-12" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r919": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r920": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r921": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479365/842-20-25-6" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } }